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Abstract 
Background: The microvasculature of solid tumours is characterized by 
profound structural and functional abnormality, which mediates several 
deleterious aspects of tumour behavior. As such, the development of therapeutic 
strategies to mitigate vascular dysfunction within tumours is an important goal. 
The Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP) attenuates the 
activity of the endothelial cell (EC) Tie-2 receptor tyrosine kinase, a key mediator 
of vessel maturation. In this study, I aimed to determine the effects of 
pharmacological VE-PTP inhibition on EC Tie-2 receptor activation and the 
resultant impact on breast cancer angiogenesis, progression, metastasis and 
treatment.  
Methods: AKB-9778 is a first-in-class VE-PTP inhibitor. I examined its effects on 
ECs in vitro and on embryonic angiogenesis in vivo using zebrafish assays. The 
impact of AKB-9778 therapy on the solid tumour vasculature was studied using 
orthotopic models of primary murine mammary carcinoma as well as both 
spontaneous and experimental models of metastasis. Finally, I used endothelial 
nitric oxide synthase (eNOS) deficient mice to establish the causal role of eNOS 
in mediating the effects of VE-PTP inhibition.  
Results: AKB-9778 induced ligand-independent Tie-2 activation in ECs and 
impaired embryonic zebrafish angiogenesis. In mouse models of breast cancer, 
AKB-9778 (i) delayed the early phase of tumour growth by enforcing vascular 
maturity; (ii) slowed progression of micrometastases by preventing extravasation 
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of tumour cells into distant organs (prolonging survival); and (iii) stabilized 
established primary tumour vessels, enhancing tumour blood perfusion and 
radiation response. The effects of AKB-9778 on tumour vessels were mediated in 
part by eNOS activation.  
Conclusions: The results demonstrate that pharmacological VE-PTP inhibition 
can normalize the structure and function of tumour vessels through Tie-2 
activation. This vascular normalization delays tumour growth and metastasis, and 
enhances response to concomitant cytotoxic treatments. 
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1 Chapter One: Introduction 
1.1 Introduction 
The establishment of a mature, organized vascular network is fundamental for 
tissue homeostasis.  Therefore, creation of new blood vessels, angiogenesis, 
plays a critical role in health and development. Angiogenesis is vital for 
successful embryogenesis and organ growth, and is also an important 
requirement for wound healing and tissue repair.  In such situations, 
angiogenesis is a tightly regulated process, as its onset and offset are carefully 
controlled by a host of molecular and mechanical factors (Jain, 2003, Dvorak, 
1986).  This strict regulation results in a tissue-specific, structured, hierarchically 
organized vascular tree that is optimally positioned to meet the needs of the 
organ and of the body. 
In contrast, many human diseases are associated with vascular dysfunction of 
some sort.  When Celsus described the four cardinal features of inflammation – 
tumour, rubor, calor, dolor – in the First Century AD, he provided the first report 
of the phenotype associated with the microvascular dilation and 
hyperpermeability that is classical of several inflammatory diseases.  In more 
recent times, increased attention has been given to disorders characterized not 
only by a dysregulation of vascular function, but also associated with 
uncontrolled angiogenesis.  In such conditions, new blood vessel development 
occurs in a disorganized fashion (Jain, 2005, Mazzone et al., 2009, Morikawa et 
al., 2002, Hashizume et al., 2000, Gazit et al., 1997, Nagy et al., 2009). Solid 
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cancers are the prototypic example of a disease state associated with 
pathological angiogenesis, which has become a vibrant area of research.  Other 
common and important diseases such as inflammatory disorders and 
atherosclerosis (Jain et al., 2007, Sidky and Auerbach, 1975, Leibovich et al., 
1987, Orlandi et al., 1988, Bo et al., 1992), and more rare conditions such as 
certain benign tumours and age-related macular degeneration (Carmeliet and 
Jain, 2000) are other examples of diseases associated with an abnormal 
vasculature. 
The concept that growing tumours have a rich vascular network first arose well 
over one hundred years ago, through observations by notable scientists such as 
Virchow (Ferrara, 2002), and was strengthened by the seminal work of Ide (Ide et 
al., 1939) and later Algire (Algire and Chalkley, 1945) who confirmed the 
importance of an abundant blood supply to tumour growth.  In 1968, the 
hypothesis that tumours produce a diffusible factor that promotes angiogenesis 
was put forward (Greenblatt and Shubik, 1968, Ehrmann and Knoth, 1968), 
forming the foundation for Dr Judah Folkman’s seminal paper in 1971 in which he 
suggested that the identification of key molecular players driving tumour 
angiogenesis could result in effective strategies to inhibit it, and hence “starve” a 
tumour to death (Folkman, 1971). Following this, Gullino demonstrated in 1976 
that cells in pre-cancerous tissue acquire angiogenic capacity on their way to 
becoming cancerous, and suggested anti-angiogenesis as a strategy to prevent 
cancer (Gullino, 1978).  Over the last four decades, these findings have spurred 
a very significant research effort, which has culminated in the introduction of 
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several anti-angiogenic medications into modern clinical practice. With this 
success came also very important questions related to the mechanism of action 
of antiangiogenic agents in patients.  
Tumour angiogenesis is not simply the production of an increased number of 
blood vessels to serve a growing mass.  Although the main purpose of tumour 
angiogenesis can be considered to maintain a cancer’s blood supply, the process 
occurs in an unmitigated fashion and the resultant vessel network is highly 
abnormal.  This stands in contradistinction to wound healing, in which 
angiogenesis is tightly regulated (Dvorak, 1986, Chung et al., 2010).  Indeed, this 
relentless drive for angiogenesis led Dvorak to elegantly describe tumours as 
“wounds that do not heal” (Dvorak, 1986).  This profoundly aberrant vasculature 
dramatically alters the tumour microenvironment, and influences heavily the ways 
in which cancers grow and progress, escape the host’s immune system, 
metastasize, and respond to anticancer therapies.   
In order to obtain nutrients for their growth and for dissemination to distant 
organs, cancer cells engulf existing blood vessels (vascular co-option) or form 
new blood vessels.  The latter can take one of three forms: (i) new blood vessel 
sprouting from existing vessels (angiogenesis); (ii) recruitment of bone marrow 
derived endothelial progenitor cells to form new vessels (postnatal 
vasculogenesis); and (iii) intussusception, when a capillary wall extends into the 
lumen to split a single vessel into two (also known as splitting angiogenesis) 
(Patan et al., 1996, Carmeliet and Jain, 2000, Baum et al., 2010).  Two further 
emerging mechanisms of vessel formation in tumours include vasculogenic 
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mimicry (the trans-differentiation of cancer cells) and mosaic vessel formation 
(the incorporation of cancer cells into the vessel wall) (Folberg et al., 1993, Ricci-
Vitiani et al., 2010, Hammersen et al., 1985).  All of these processes are driven 
by a number of molecular players.  Of these, a critical factor is the Vascular 
Endothelial Growth Factor A (VEGF-A, also known as VEGF).  VEGF was first 
discovered by Dvorak and colleagues as a “Vascular Permeability Factor” (VPF) 
in 1983 (Senger et al., 1983), and later by Ferrara and colleagues as the 
angiogenic endothelial mitogen (named VEGF) in 1989 (Leung et al., 1989).  At 
the same time, it was reported that VPF and VEGF were the same molecule 
(Keck et al., 1989), and that the VEGF Receptor 2 (VEGFR2) (Terman et al., 
1992) is the main endothelial cell mediator of VEGF’s pro-angiogenic activities 
(Millauer et al., 1993).  Since these landmark discoveries, a catalogue of other 
molecular players has been established in the process of tumour angiogenesis.  
The chronic imbalance of the pro- and anti-angiogenic signaling in tumours (ie. 
an excess of pro-angiogenic signaling, a deficiency of anti-angiogenic signaling, 
or both) leads to the development of the abnormal tumour vasculature. 
1.2 The role of abnormal vasculature in tumour progression and 
treatment-resistance 
1.2.1 The abnormal structure of the tumour vasculature 
Overexpression of VEGF and other pro-angiogenic factors leads to formation of a 
new vasculature that is structurally abnormal at both macroscopic and 
microscopic levels (Fukumura et al., 2010, Gazit et al., 1997, Jain, 2003, Nagy et 
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al., 2002, Nagy et al., 2009).  These abnormalities are exacerbated as a tumour 
continues to grow (Gazit et al., 1997).  Anatomically, tumour microvessels are 
dilated, tortuous, and saccular with haphazard patterns of interconnection and 
branching (Kim et al., 2010, Jain, 2005, Less et al., 1991, Less et al., 1997).  Of 
particular relevance to this thesis, this vessel phenotype has been observed in 
preclinical models of breast cancer (Tong et al., 2004, Yuan et al., 1996).  Unlike 
the microvasculature of normal tissue, which has an organized and regular 
branching pattern, tumour vasculature is characterized by pockets of increased 
vessel density and others of reduced vessel density (Less et al., 1991, Less et 
al., 1997, Baish et al., 2011, Baish and Jain, 2000).  There is also increased 
vascular shunting within tumours, caused by a loss of vascular diameter control, 
an increase in vascular reactivity, and a higher tendency for vessel growth (Pries 
et al., 2009, Pries et al., 2010).   
At the cellular level, the endothelial cells (ECs) lining tumour vessels have an 
irregular, disorganized morphology. Mature, stable ECs are connected by 
adherens junctions including vascular endothelial-cadherin (VE-Cadherin) 
(Dejana et al., 2009). VE-Cadherin is a transmembrane receptor, the 
extracellular domain of which binds to other VE-Cadherin molecules on 
neighboring ECs.  The intracellular domain of VE-Cadherin attaches to the EC 
cytoskeleton via the catenin family of proteins, acting as structural links but also 
effectors for downstream molecular signaling (Dejana et al., 2009). Downstream 
signaling from VEGF-VEGFR2 interactions promotes contraction of the 
endothelial cell cytoskeleton and weakening of VE-Cadherin junctions, and 
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hence a loosening of EC associations and EC migration (Dejana et al., 2009).  
As a consequence, ECs within tumours are often poorly connected or 
overlapping, with less VE-Cadherin and a branched phenotype with long 
cytoplasmic projections (Hobbs et al., 1998, Hashizume et al., 2000).  At times, 
ECs might protrude into the capillary lumen, or conversely sprout into the 
perivascular tumour tissue (Hashizume et al., 2000).  There is also an 
abundance of vesiculo-vacuolar organelles (VVOs) in tumour EC’s, which have 
been associated with vascular permeability, however these do not explain the 
large gaps in the walls of tumour vessels (Hobbs et al., 1998, Qu et al., 1995).   
In addition, perivascular cells (PVCs) – both pericytes and vascular smooth 
muscle cells – around tumour vessels demonstrate abnormal structural 
characteristics. These connective tissue cells normally surround and support the 
endothelium.  Pericytes usually lie within the vessel basement membrane, and 
interact closely with ECs to prevent vessel leakage.  They are normally recruited 
to stabilize vessels and hence envelop ECs in response to activation of a number 
of molecular pathways: (i) platelet-derived growth factor B (PDGF-B), which is 
secreted by ECs and facilitates pericyte recruitment to vessels through binding to 
the platelet-derived growth factor receptor-β (PDGFRβ) on pericytes; (ii) 
angiopoietin-1 (Ang-1), a vascular stabilizing factor that facilitates pericyte-EC 
connections; (iii) sphingosine-1-phosphate-1 (S1P1) and endothelial 
differentiation sphingolipid G-protein–coupled receptor 1 (EDG1); and (iv) 
transforming growth factor-β (TGF-β) (Jain, 2003).  
Dysregulation of these vessel maturation pathways in tumours often results in 
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vessels with an absent or loose attachment of PVCs (Abramsson et al., 2003, 
Inai et al., 2004, Jain, 2003, Tong et al., 2004), including those of mammary 
carcinomas (Morikawa et al., 2002).  PVC detachment is an early step in the 
process of tumour angiogenesis, and facilitates the movement of ECs into the 
surrounding matrix to form new vessels.  Moreover, these PVCs are often 
abnormal in shape with bizarre cytoplasmic processes, irregularly scattered 
around the endothelium (Morikawa et al., 2002). The mechanisms for PVC 
detachment in tumours are multiple, but include a VEGF-mediated disruption of 
PDGFR-β activity (Greenberg et al., 2008), and overexpression of Ang-2, the 
endogenous “antagonist” of Ang-1 (Augustin et al., 2009). Moreover, detached 
PVCs become activated, releasing further VEGF and the basic fibroblast growth 
factor (bFGF), setting up a vicious cycle of continuous angiogenesis (Raza et al., 
2010, Fukumura et al., 1998, Brown et al., 2003).  Finally, the vascular basement 
membrane in tumour tissue is also abnormal: unusually thick in some tumours 
(eg. in the brain), or completely absent in others (Inai et al., 2004, Kamoun et al., 
2009, Tong et al., 2004, Winkler et al., 2004).  
1.2.2 Functional consequences of an abnormal tumour vasculature 
The structural abnormalities of the tumour vasculature have far-reaching 
consequences for tumour pathophysiology, growth, metastasis, and response to 
anti-cancer therapies.  Just as the aberrations in cancer cells promote their 
survival and resistance to treatments, the genetic and epigenetic abnormalities of 
the tumour microvasculature result in pathophysiological traits that are 
functionally advantageous for most cancers. 
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Firstly, the heterogeneity in vessel distribution and haphazard anatomical 
arrangement of the vasculature cause spatial and temporal heterogeneity in 
blood flow (Jain, 1988, Jain, 2005), with areas of hypervascularity adjacent to 
hypovascular ones (Baish et al., 2011, Tong et al., 2004).  Furthermore, blood 
flow in solid tumours, including mammary carcinomas, is often redundant in 
closed or blind loops (Less et al., 1991, Less et al., 1997).  Secondly, the 
structural abnormalities described above lead to a marked increase in vessel 
leakiness.  Poorly connected ECs, loosely associated PVCs, and an increase in 
VVOs all contribute to this hyperpermeable phenotype, and hence intravascular 
fluids and plasma proteins can easily extravasate (Jain, 2005, Greenberg et al., 
2008, Hamzah et al., 2008, Morikawa et al., 2002). As a consequence, there is a 
protein and fluid build-up in the tumour interstitium.  This excess extravasation of 
proteins increases the extravascular oncotic pressure (osmotic pressure of 
plasma proteins), dragging further fluid into the interstitial space (Tong et al., 
2004, Stohrer et al., 2000).  Furthermore, there is an absence of functional 
intratumoural lymphatic vessels, resulting in the impaired clearance of 
extracellular fluid and hence interstitial hypertension within tumours.  This 
elevated interstitial fluid pressure (IFP) has been documented within murine and 
human tumours, including breast, colorectal, and cervical cancer as well as 
melanoma and glioblastoma (Boucher et al., 1997, Boucher et al., 1990, Boucher 
et al., 1991, Lee et al., 2000, Less et al., 1992, Leunig et al., 1992, Roh et al., 
1991, Willett et al., 2004, Willett et al., 2009).  The raised intratumoural IFP 
reduces the hydrostatic pressure gradient between the intravascular and 
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extravascular compartments such that the two essentially equilibrate.  Although 
this in itself is not sufficient to collapse tumour vessels, it does reduce 
transvascular flow (as per Starling’s equation describing fluid movement across 
the vascular wall (Starling, 1896)).  On the other hand, the mechanical stress 
from the solid mass of proliferating cancer cells and the matrix is able to collapse 
tumour vessels, closing their lumen through compressive forces (Padera et al., 
2004).  This combination of regional poor perfusion, raised IFP, and areas of 
vascular collapse produces regional hypoxia and acidosis within tumours 
(Helmlinger et al., 1997).  Indeed, Vaupel and colleagues measured the partial 
pressure of oxygen in tumours using electrodes, and demonstrated the presence 
of hypoxia within several different human tumour types (Hockel et al., 1999, 
Hockel and Vaupel, 2001).   
The anomalous tumour vasculature and the ensuing hypoxia have several 
consequences for tumours beyond promotion of angiogenesis. Firstly, because 
cancer cells are more resistant to hypoxia than normal cells, they undergo 
epigenetic changes in hypoxic conditions that promote their malignant phenotype 
and the epithelial-to-mesenchymal transition (EMT).  This may result in a greater 
metastatic potential (Bottaro and Liotta, 2003, DeClerck and Elble, 2010, Hockel 
et al., 1999, Semenza, 2010a, Semenza, 2010b).  For example, hypoxia induces 
HIF1a-mediated production of several growth factors in cancer cells (Harris, 
2002), and the activation of oncogenes that promote invasive growth and 
metastasis (Pennacchietti et al., 2003).  In addition, hypoxia can upregulate 
expression of VEGF-C in tumour cells, promoting lymphatic metastasis 
  25 
(Morfoisse et al., 2014). Indeed, increased hypoxia also correlates with 
metastasis and reduced survival in patients (Hockel et al., 1999). Secondly, 
hypoxia and low pH also compromise the cytotoxic functions of immune cells that 
infiltrate a tumour, further enhancing the malignant phenotype (Ganss et al., 
2004).  Thirdly, aberrations in the tumour vasculature have great implications for 
tumour sensitivity to therapy.  Hypoxia is a well-known mediator of cancer cell 
resistance to conventional radiotherapy and cytotoxics (Wouters and Brown, 
1997, Teicher, 1996). Moreover, the poor blood supply and raised intratumoural 
IFP (leading to a reduction in transvascular flow) impair the delivery of 
systemically administered therapies to tumours such as conventional cytotoxics 
and monoclonal antibodies (Jain, 1989, Wildiers et al., 2003, Tong et al., 2004).   
Drugs become concentrated in regions that already have sufficient blood supply, 
and fail to enter inaccessible regions.   
1.3 Vascular normalization – a therapeutic strategy in solid tumours 
1.3.1 The Vascular Normalization hypothesis 
Systemic anti-angiogenic therapy has been developed with the rationale that 
inhibiting blood vessel formation would cause profound vascular regression, 
essentially starving tumours to death or rendering them “dormant” (Folkman, 
1971).  Early preclinical studies provided support for this hypothesis.  In various 
xenograft models, anti-VEGF monoclonal antibodies hindered tumour 
angiogenesis and delayed tumour growth (Kim et al., 1993, Warren et al., 1995). 
  26 
Despite these promising preclinical results, the effects of anti-VEGF 
monotherapy in the treatment of human solid tumours have been generally 
underwhelming, with only modest objective response rates and a lack of 
meaningful survival benefits in phase 3 trials (Jain et al., 2006).  In metastatic 
colorectal cancer, for example, an objective response rate of 3.3% was observed 
amongst chemotherapy-pretreated patients receiving monotherapy with 
bevacizumab, a monoclonal antibody against human VEGF (Giantonio et al., 
2007).  Similar results were observed in a breast cancer population (Cobleigh et 
al., 2003).  Such data suggest that anti-VEGF therapy alone is unable to 
effectively induce sufficient vascular regression in the clinical setting to cause 
significant tumour shrinkage.  
In contrast, large randomized phase 3 clinical trials of bevacizumab therapy in 
combination with systemic chemotherapy have demonstrated significant 
improvements in progression-free and overall survival when compared with 
systemic chemotherapy alone.  Multiple clinical trials in the first- and second-line 
treatment of metastatic colorectal cancer have all confirmed that the addition of 
bevacizumab to standard first-line chemotherapy regimens significantly improves 
patient outcomes (Hurwitz et al., 2004, Tebbutt et al., 2010, Saltz et al., 2008). 
Trials of bevacizumab with chemotherapy as first-line treatment for metastatic 
non-small cell lung cancer have yielded similar results (Sandler et al., 2006, Reck 
et al., 2009).  Additionally, initial studies in metastatic breast cancer suggested a 
significant improvement in progression-free survival from the addition of 
bevacizumab to standard cytotoxic chemotherapy (Miller et al., 2007).  Although 
  27 
in the case of breast cancer this did not translate into an improvement in overall 
survival (Miles et al, 2010, Brufsky et al, 2011, Robert et al., 2011), such data are 
intriguing, and collectively imply that anti-VEGF antibody therapy augments the 
efficacy of systemic chemotherapy but has limited action as a monotherapeutic.  
Taken together, there appears to be a synergistic effect upon combining anti-
VEGF antibody therapy with chemotherapy.  
These clinical results seem counter-intuitive.  Anti-VEGF therapy is designed to 
promote vascular regression and tumour starvation, and yet the efficacy of 
chemotherapy depends on efficient tumour blood flow and hence drug delivery. 
Thus, vascular regression should theoretically dampen, rather than enhance, the 
effects of systemic chemotherapy.  In addition, tumour hypoxia induced by the 
antivascular effects anti-VEGF therapy should also increase the metastatic 
proclivity of tumours and render them relatively chemoresistant (Pennacchietti et 
al., 2003).  The trial results refute these hypotheses, however, and are further 
supported by the fact that no trial in patients with metastatic disease has 
demonstrated a significant detriment in overall survival from the addition of 
bevacizumab to systemic chemotherapy (Miles et al., 2011, Welch et al., 2010, 
Padera et al., 2008). 
The “vascular normalization” hypothesis is an attempt to resolve this paradox 
(Jain, 2001, Jain, 2005).  The hypothesis posits that rather than obliterating 
vessels, the judicious use of anti-angiogenic therapy reverts the grossly 
abnormal structure and function of the tumour vasculature towards a more 
normal state.  In turn, this normalizes the tumour microenvironment.   
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1.3.2 Consequences of vascular normalization in tumours 
The normalization hypothesis suggests that by correcting the abnormalities in 
structure and function of tumour vessels (rather than destroying vessels 
completely), we can rectify aberrations in the tumour microenvironment and 
ultimately control tumour progression and improve response to other therapies 
(Jain, 2001, Jain, 2005).  This may occur via different physiological mechanisms. 
Firstly, increased homogeneity of functional vascular density and a more orderly 
arrangement of vessels could reduce heterogeneity in blood flow in different 
regions within a tumour.  Secondly, improved connections between adjacent 
endothelial cells, an increased proportion of PVC-covered vessels, and a tighter 
association between PVCs and ECs would reduce vascular permeability, 
resulting in a drop in intratumoural IFP.  While tumour vessels may never 
become completely “normal” the effect of these changes is a more even 
distribution of blood flow within a tumour, with a subsequent reduction in areas of 
hypoxia and acidosis.  In turn, one would expect amelioration of the hypoxia-
mediated increase in cancer cell metastatic potential, more uniform delivery of 
systemically administered anti-cancer therapies within a tumour, and enhanced 
radiosensitivity of tumours.  This might serve to explain the seemingly 
paradoxical clinical trial data demonstrating synergism between anti-VEGF 
therapy and chemotherapy in the treatment of solid tumours.  
1.3.3 Molecular mechanisms of vascular normalization 
In normal tissues, the collaborative action of various proangiogenic factors (eg. 
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VEGF, basic fibroblastic growth factor [bFGF], angiopoietin-2 [Ang-2]) is in 
balance with the action of endogenous antiangiogenic and vascular stabilizing 
factors (eg. Thrombospondin-1 [TSP-1], Ang-1) (Goel et al., 2011, Winkler et al., 
2004, Chae et al., 2010, Bocci et al., 2003, Watnick et al., 2003, Thurston et al., 
1999, Maisonpierre et al., 1997, Relf et al., 1997). In pathological angiogenesis, 
an imbalance persists leading to the relentless development of aberrant vessels.  
By attempting to redress this imbalance, it is possible to normalize tumour 
vessels.  One validated mechanism of vascular normalization is blockade of 
VEGF signaling.  Inhibition of VEGF – a factor that promotes the survival and 
proliferation of ECs and increases vascular permeability – can transiently restore 
the balance between pro- and antiangiogenic signaling, shifting it back towards 
equilibrium.  
Over time, a number of other key angiogenic molecules and genes have been 
directly implicated in the development of an abnormal tumour vasculature and 
the normalization process.  In total, over three hundred original published 
manuscripts describe evidence of the normalization process as a result of 
inhibition of any of several different pro-angiogenic pathways, both preclinically 
and in patients.  A detailed description of these is beyond the scope of this 
thesis, but they are summarized in Figure 1 and reviewed in Goel et al, 2011.   
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Figure 1: Factors shown to promote or inhibit the vascular normalization phenotype in tumours. This schematic depicts a tumour cell 
(green), endothelial cell (beige), pericytes (blue), and the extracellular matrix. Molecules that lead to characteristic vessel abnormalities 
are in red, and those that promote the normalization phenotype are in blue. The principal angiogenic molecule responsible for vascular 
abnormalities is VEGF-A. This is produced by tumour cells (in reponse to hypoxia via the PHD2/HIF pathway; or due upregulation by 
oncogenic activation (Izumi et al., 2002, Schnell et al., 2008, Cerniglia et al., 2009, Qayum et al., 2009), sex hormones (Jain et al., 1998, 
Hansen-Algenstaedt et al., 2000), inflammatory cytokines, etc.). VEGF-A may also be derived from tumour-infiltrating myeloid cells, 
pericytes, or released from the extracellular matrix, and acts primarily via VEGFR2 on ECs. In addition, VEGF-A stimulation of VEGFR2 
on pericytes inhibits PDGFB-PDGFRβ mediated pericyte recruitment to ECs (Greenberg et al., 2008). In addition, PlGF may contribute to 
tumour vessel abnormalities (possibly by changing the number or phenotype of macrophages), potentially acting through the VEGFR1 or 
NRP1 (Mazzone et al., 2009). Other mediators of the abnormal vessel phenotype shown include Ang-2 (acting on the Tie-2 receptor – 
(Maisonpierre et al., 1997)), Rgs5 (which inhibits PDGFR-mediated pericyte recruitment – (Hamzah et al., 2008, Gunaje et al., 2011)), 
and tumour cell integrins (in the case of GBM). Factors that may restore tumour vessels toward a more normal phenotype include Ang-1 
(derived primarily from perivascular cells and acting on Tie-2 – (Suri et al., 1996)), SEMA3A, PDGF-B, and other factors whose 
mechanism of action is less clear (eNOS, PDGF-C, PDGF-D, IFN-β, TSP-1). Importantly, the differential effects of hypoxia in the tumour 
cell and endothelial cell are to potentially “abnormalize” or normalize vessels, respectively. Ang, Angiopoietin; EGFR, epidermal growth 
factor receptor; eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase; GBM, glioblastoma multiforme; HER2, human 
epidermal growth factor receptor 2; HIF, hypoxia inducible transcription factor; IFN, interferon; MMP, matrix metalloproteinase; NRP, 
neuropilin; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PHD, prolyl hydroxylase domain 
protein; PI3K, phosphoinositide-3-kinase; PlGF, placental growth factor; Rgs5, regulator of G protein signaling 5; SEMA, semaphorin; 
sFlt1, soluble VEGFR1; TSP, thrombospondin; VE-cadherin, vascular-endothelial cadherin; VEGF, vascular endothelial growth factor; 
VEGFR, vascular endothelial growth factor receptor; α, β, and γ refer to alpha-, beta-, and gamma-catenin, respectively.  (Adapted from 
Goel et al, 2011). 
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1.4 Sustained normalization: an elusive goal 
Ideally, vascular normalization within tumours would be a sustained process, 
facilitating a constant improvement in perfusion and reduction in tumour hypoxia. 
Indeed, various genetic studies have achieved this goal. For example, tumours 
growing in mice haploinsufficient for PHD2, or in Rgs5 null mice, show evidence 
of a sustained, normalized vessel phenotype characterized by improved 
perfusion, reduced hypoxia, and the attendant improved efficacy of concomitantly 
administered anti-cancer therapies (Hamzah et al., 2008, Mazzone et al., 2009).   
Unfortunately, pharmacologically induced vascular normalization is transient, and 
characterized by a narrow “time window”. This refers to the time period after 
commencement of anti-angiogenic therapy during which vessels demonstrate 
features of the normalization phenotype.  Studies of murine and human tumours 
have identified the onset of normalization, typically 1-2 days after 
commencement of therapy, followed by an eventual “closure” of the 
normalization window, at which point features of normalization are lost (Kamoun 
et al., 2009, Winkler et al., 2004, Willett et al., 2004).  This may relate either to 
excessively high or prolonged dosing of antiangiogenic therapy (ie. tipping the 
balance past equilibrium in favour of antiangiogenic molecules, leading to 
vascular pruning/regression), or to the development of resistance by activation of 
alternative proangiogenic pathways or modes of acquiring new vessels. 
Importantly, it has been shown that cancer cells are more vulnerable to cytotoxic 
therapies specifically whilst the window is open, and thus defining its timing in a 
variety of situations is of critical importance (Winkler et al., 2004).  Given the tight 
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balance between excessive and insufficient angiogenesis within tumours, 
attainment of a sustained, pharmacologically induced vascular normalization has 
thus far proved an elusive goal.  Indeed, the functional vascular phenotype seen 
following treatment with anti-angiogenic therapies for cancer is likely to reflect the 
balance between the degree of vascular regression and vascular normalization, 
both of which are likely to occur concurrently within the same tumour.  
1.5 The Angiopoietin-Tie2 system: a key mediator of vascular 
abnormalities in tumours 
After the VEGF-VEGFR system, the next best characterized molecular pathway 
involved in regulation of angiogenesis and vessel maturation is the Angiopoietin-
Tie2 axis, which plays a key role in regulating both physiological and pathological 
angiogenesis (Huang et al., 2010, Suri et al., 1996).   
Ang-1 and Ang-2 bind to their cognate receptor tyrosine kinase Tie-2 on the EC 
surface.  Ang1 is synthesized by PVCs and serves as a Tie-2 agonist.  Activated 
Tie-2 binds to and activates a number of downstream effector molecules within 
ECs, including endothelial nitric oxide synthase (eNOS), the PI3-Kinase catalytic 
complex, growth factor receptor-bound protein 2 (GRB2), and A20-binding 
inhibitor of nuclear factor-κB activation 2 (ABIN2) (Huang et al., 2010).  
Ultimately, this promotes EC survival, inhibits EC apoptosis, and supports 
endothelial quiescence.  The resultant phenotype is one of vascular stability, 
maturity, and integrity (Augustin et al., 2009).  In keeping with this, Tie-2 
activation by Ang-1 has been shown to reduce vascular permeability (Thurston et 
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al., 1999, Thurston et al., 2000, Wong et al., 1997, Gamble et al., 2000), and also 
increases vessel diameter and hence blood flow (Suri et al., 1998).   
In contrast, Ang-2 is synthesized primarily by ECs, and normally antagonizes the 
actions of Ang-1 (Maisonpierre et al., 1997).  It is the ratio of Ang-1/Ang-2 that 
determines their ultimate effects. In contrast to Ang-1, Ang-2 destabilizes 
vessels, promotes PVC detachment from ECs, and drives (especially in concert 
with VEGF) the process of pathologic angiogenesis.  In reality, the effects of Ang-
2 are more complex and in certain circumstances it can also serve as a Tie-2 
agonist (Daly et al., 2006).   
Typically, Ang-1 is constitutively expressed within normal tissues, and plays a 
key role in maintaining vessel integrity.  Conversely, Ang-2 is primarily produced 
at times when active angiogenesis or vessel remodeling is occurring (of note, 
Ang-2 is also critical in the regulation of lymphatic vessel development {Zheng et 
al, 2014)).  In both solid tumour growth and metastasis, Ang-1 levels are 
relatively constant but levels of Ang-2 are higher than those of normal tissue 
(Holash et al., 1999, Koh et al., 2010).  In various stages of tumour development, 
this increased production of Ang-2 facilitates vessel destabilization and hence 
encourages tumour growth. 
In the earliest phases of primary tumour growth, tumour cells co-opt normal host 
vessels, leading them to upregulate Ang-2 production.  This in turn facilitates the 
earliest steps that permit the onset of sprouting angiogenesis (Holash et al., 
1999), and the beginnings of an abnormal vasculature.  Similarly, when tumour 
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cells circulate and lodge within the vessels of distant organs, it is the production 
of Ang-2 by these vessels that destabilizes them and permits tumour cell 
extravasation and tumour cell colonization (Holash et al., 1999, Holopainen et al., 
2012, Avraham et al., 2014, Rodriguez et al., 2014).  Finally, in established 
primary tumours, levels of Ang-2 continue to rise as tumours enlarge, and in 
concert with VEGF drive the abnormal, immature vessel phenotype (Koh et al., 
2010).  Consistent with this, recent data also suggests that Ang-2 may serve as a 
direct mediator of resistance to anti-VEGF therapy in mammary carcinomas 
(Rigamonti et al., 2014), with Ang-2 levels rising in direct response to VEGF 
blockade.   
The Angiopoietin-Tie2 system has been studied using genetic approaches, and 
evidence supports previously established notions that EC-derived Ang-2 is an 
important “abnormalizing” factor.  When Ang-2 knockout mice are implanted with 
syngeneic carcinoma or melanoma, the resultant tumours show various features 
similar to those reported with pharmacological anti-Ang2 therapy (Falcon et al., 
2009, Nasarre et al., 2009), including a reduction in vessel diameter, an increase 
in tumour perfusion and a more mature PVC profile.   
Furthermore, Ang-1 is required for the establishment of a stable, normalized 
vasculature in the face of VEGF pathway blockade (Winkler et al., 2004), and an 
excess of Ang-2 compromises this process (Chae et al., 2010). 
Therefore, a reduced Ang-1:Ang-2 ratio, and the consequent decline in Tie-2 
activity, is an important determinant of  tumour vessel abnormalities. 
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1.6 Targeting the Angiopoietin-Tie2 system in solid tumours 
In recent years, a number of pharmacologic agents have been developed to 
target the abnormal tumour vasculature caused by excessive Ang-2 activity 
(Huang et al., 2010).  Several preclinical studies using these agents have shed 
further light on the role of the Ang-Tie2 axis in tumour vasculature. 
A study using specific pharmacological blockade of Ang-1 and Ang-2 (Falcon et 
al., 2009), highlighted the requirement of Ang-1 for vascular normalization and 
the contribution of Ang-2 to vascular abnormalities.  Nude mice bearing colon 
cancer xenografts were treated with ML4-3 (a peptibody specifically neutralizing 
Ang-1), Li-7 (a peptibody specifically neutralizing Ang-2), or their combination.  
Treatment with ML4-3 alone did not affect tumour growth or vascular 
morphology, and vessels remained immature and disorganized as evidenced by 
faint, irregular deposition of VE-Cadherin.  Neutralization of Ang-2 with Li-7 
normalized vessels.  In particular, vessels were narrower and more uniform in 
morphology with less tortuosity. In addition, increased pericyte coverage was 
observed and there was a tightening of association between pericytes and ECs, 
which showed uniform linear deposition of VE-Cadherin.  Finally, when tumours 
were subjected to combined Ang-1 and Ang-2 blockade, vessel density reduced 
but vessels remained disorganized with irregular VE-Cadherin staining.  These 
data are consistent with those seen after anti-VEGFR2 treatment of 
glioblastomas (Chae et al., 2010, Winkler et al., 2004). 
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Recently, a number of reports detailing the effects of other anti-Ang-2 strategies 
(including anti-Ang-2 antibodies) in solid tumours and inflammatory diseases 
have been reported (Brown et al., 2010, Tabruyn et al., 2010, Huang et al., 2011, 
Zheng et al, 2014).  Together, they show inhibition of tumour growth, reduction in 
tumour vessel density, and remodeling of the vasculature suggesting that 
targeting Ang-2 may prove a valuable method to exploit the benefits of vascular 
normalization.  Of relevance to this thesis, it is noteworthy that the ongoing I-
SPY2 clinical trial is studying the effects of an anti-angiopoeitin 1/2 “peptibody” - 
AMG-386 – as neoadjuvant therapy for breast cancer (Barker et al., 2009).   
In addition, a dual pharmacological inhibitor of VEGF and the angiopoietins 
(named the “Double anti-angiogenic protein”, DAAP) has been developed and 
studied preclinically (Koh et al., 2010).  DAAP, a chimeric decoy receptor that 
simultaneously binds VEGF and Ang1/2, was shown to inhibit the growth of 
several murine tumours, and in the case of implanted ovarian carcinoma, 
resulted in a normalization of vessels in the peritoneum – characterized by 
reduced vessel diameter and a more organized vascular hierarchy.  These 
effects are likely mediated by suppression of the activities of VEGF and Ang-2, 
given their propensity to promote tumour angiogenesis (Koh et al., 2010).  
In general, agents targeting this axis are designed to shift the Ang1:Ang2 ratio in 
favor of Ang1, hoping to diminish Ang-2-mediated angiogenesis and stabilize 
vessels.   Intriguingly, a recent clinical study has provided preliminary data 
suggesting that patients with higher levels of circulating Tie2 have an improved 
outcome after neoadjuvant chemotherapy for breast cancer, further supporting 
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the importance of the angipoeitin-Tie2 axis as a mediator of tumor behavior and 
potentially patient prognosis (Makhoul et al., 2014). 
1.7 The Vascular Endothelial Protein Tyrosine Phosphatase: an 
important regulator of Tie2 activity 
1.7.1 VE-PTP is essential for vascular development 
In 1999, Fachinger et al provided the first report of a receptor tyrosine 
phosphatase that is expressed exclusively in endothelial cells (Fachinger et al., 
1999).  This phosphatase was named the Vascular-Endothelial Protein Tyrosine 
Phosphatase (VE-PTP, human orthologue protein tyrosine phosphatase receptor 
type B, PTPRB).   
In subsequent years, work from the laboratory of Dietmar Vestweber has begun 
to characterize the structure and function of VE-PTP (Nawroth et al., 2002, 
Baumer et al., 2006, Broermann et al., 2011, Nottebaum et al., 2008, Winderlich 
et al., 2009).  VE-PTP is a membrane-spanning receptor tyrosine phosphatase, 
and is so far the only known phosphatase expressed exclusively in the 
endothelium (Kuppers et al., 2014).  Structurally, VE-PTP comprises a cytosolic 
phosphatase domain, a transmembrane domain, and an extracellular portion 
comprised of 17 fibronectin-like domains (Nawroth et al., 2002). 
The critical role of VE-PTP in endothelial function is clear, given that is essential 
for successful embryogenesis.  Two different VE-PTP deficient mouse models 
both show embryonic lethality (Baumer et al., 2006, Dominguez et al., 2007).  In 
both models, vasculogenesis occurs normally (and VE-PTP is not expressed at 
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this early stage), but there are severe defects observed due to failed 
angiogenesis – namely failure of the yolk sac vasculature to form a organized 
vascular tree, and development of large, saccular vessels (Dominguez et al., 
2007, Baumer et al., 2006).  Further supporting a role for VE-PTP in vascular 
development, Shen et al. recently showed that VE-PTP is upregulated in 
endothelial cells in response to hypoxia (Shen et al., 2014). 
1.7.2 VE-PTP is a negative regulator of Tie-2 activity 
In recent years, some of the molecular interactions of VE-PTP have been 
elucidated.  Importantly, the initial report describing VE-PTP showed that it binds 
directly to the Tie-2 receptor tyrosine kinase, but not VEGFR2 (Fachinger et al., 
1999).  Further work has clarified the nature of this interaction: Tie-2 and VE-PTP 
are associated through their cytoplasmic domains, and VE-PTP directly 
dephosphorylates tyrosine residues on Tie-2 (Winderlich et al., 2009).  Elegant 
work by Winderlich at al has shown that inhibition of VE-PTP expression by 
antibodies, siRNA, or gene disruption triggers Tie-2 tyrosine phosphorylation, 
and that by dephosphorylating Tie-2, VE-PTP serves as an important regulator of 
Tie-2 activity (Winderlich et al., 2009).  Furthermore, Ang-1 stimulation of Tie-2 
heightens the association of Tie-2 and VE-PTP.  As such, Vestweber’s team 
have posited that VE-PTP serves as a negative feedback control mechanism to 
limit the extent of Tie-2 activation by Ang-1 (Winderlich et al., 2009). 
The primary vascular defect in the VE-PTP knockout mouse is that of enlarged, 
saccular vessels that fail to form correct branch points (Baumer et al., 2006, 
  39 
Dominguez et al., 2007).  Through culture of allantois explants from VE-PTP null 
mice, it has been shown that this enlarged vessel phenotype occurs directly 
through hyperactivation of Tie-2 (Winderlich et al., 2009). 
1.7.3 Interactions between VE-PTP and VE-Cadherin 
Beyond Tie-2, VE-PTP has also been found to physically interact with the central 
EC junction adhesion molecule, VE-Cadherin.  VE-PTP and VE-Cadherin can be 
co-immunoprecipitated from EC lysates (Nawroth et al., 2002).   
The interaction between VE-PTP and VE-Cadherin seems to play an important 
role in regulating endothelial barrier integrity.  Loss of VE-PTP in EC’s is 
associated with loss of endothelial barrier function in vitro, and overexpression of 
VE-PTP in ECs has the opposite effect (Nawroth et al., 2002).  Furthermore, 
endothelial exposure to VEGF, lipopolysaccharide (LPS), neutrophils, or 
lymphocytes triggers dissociation of VE-PTP from VE-Cadherin, increased VE-
Cadherin phosphorylation, and an associated increase in endothelial layer 
permeability (Nottebaum et al., 2008, Broermann et al., 2011).    
The overexpression of VE-PTP in VE-Cadherin-transfected cells is associated 
with decreased tyrosine phosphorylation of both VE-Cadherin and also 
plakoglobin (gamma-catenin), another important component of the EC junctional 
complex.  At first glance, this would suggest that VE-PTP directly 
dephosphorylates VE-Cadherin and plakoglobin, in a similar fashion to Tie-2.  
However, overexpression of a catalytically inactive mutant form of VE-PTP has 
the precise same effect as expressing wild-type VE-PTP (Nawroth et al., 2002), 
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implying that it is in fact the interaction of the extracellular domains of VE-PTP 
and VE-Cadherin, rather than the activity of the VE-PTP phosphatase, that 
somehow regulates VE-Cadherin phosphorylation and EC barrier integrity.  In 
further support of this notion, Wessel et al recently reported that it is the 
dissociation of VE-PTP and VE-Cadherin that precedes tyrosine phosphorylation 
at its Tyr685 residue (Wessel et al., 2014) 
To summarize, the currently available data suggests that VE-PTP negatively 
regulates Tie-2 activity through its phosphatase activity, and heightens EC barrier 
function through its extracellular interaction with VE-Cadherin. 
1.7.4 VE-PTP in the tumour endothelium 
Unlike the angiopoietins, the role of VE-PTP in the solid tumour endothelium has 
been essentially unexplored.  In one report, implantation of murine lung 
carcinoma cells subcutaneously resulted in rapid overexpression of VE-PTP in 
host endothelial cells (Dominguez et al., 2007).  This observation leads one to 
speculate that VE-PTP activity, possibly by deactivating Tie-2, might play a role 
in the initial destabilization of tumour vessels.  This remains to be proven, 
however. 
1.8 AKB-9778 – a first-in-class inhibitor of the VE-PTP catalytic 
domain 
AKB-9778 (Aerpio Therapeutics, Cincinnati OH) is a novel, first-in-class small 
molecule inhibitor of the VE-PTP phosphatase domain.  AKB-9778 was 
developed through structural modifications of 1,2,3,4-tetrahydroisoquinolinyl 
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sulfamic acids. These acids are phosphotyrosine mimetics, and act competitively 
to prevent phosphatases from dephosphorylating their endogenous targets.  
Coupling 1,2,3,4-tetrahydroisoquinolinyl sulfamic acids to a malonate template 
yields selective and potent inhibitors of VE-PTP (Amarasinghe et al., 2006).  The 
phenylsulfamic acid moiety acts as a general phosphotyrosine mimetic 
“warhead”, and surrounding moieties were optimized as part of an extensive 
structure-based drug design program (Shen et al., 2014). 
In vitro enzyme kinetic studies show that AKB-9778 is a selective inhibitor of VE-
PTP, with over 7000-fold higher potency for VE-PTP that the generic intracellular 
phosphatase PTP1B.  Furthermore, it is over 5000-fold more selective for VE-
PTP than other phosphatases including HPTP-epsilon, CD45, Shp1, Shp2, MKP-
1, HCPTA, PTP-mu, PRL-3, VHR, PTEN, and alkaline phosphatase (Shen et al., 
2014).  
As described earlier, the central bona fide function of the phosphatase domain of 
VE-PTP appears to be dephosphorylation of Tie-2.  Therefore, it is plausible that 
by inhibiting VE-PTP, AKB-9778 might serve to enhance Tie-2 signaling within 
ECs.  Consistent with this hypothesis – and published after the experiments in 
this thesis were completed – a report from Shen et al. has recently demonstrated 
that through Tie-2 activation, AKB-9778 stabilizes retinal vessels in mice with 
neovascular macular degeneration (Shen et al., 2014), reducing permeability and 
inhibiting pathological vascularization.  Indeed in this light, AKB-9778 has now 
entered clinical trials for patients with diabetic macular oedema, and unpublished 
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data demonstrate a significant reduction in retinal oedema in a proportion of 
patients (Aerpio Therapeutics, 2014).   
The neovasculature of the diabetic eye is often compared to the vasculature of 
solid tumours, and the results above therefore provide further support for study of 
AKB-9778 as a promoter of vascular stability within tumours.  
1.9 The current study 
The present study has two central aims.   
The first is to characterize the effects of AKB-9778 as an inhibitor of the VE-PTP 
catalytic domain.  We speculated that by reducing Tie-2 dephosphorylation, AKB-
9778 might mediate an enhancement of Tie-2 signaling in EC’s.   
The second, and most important, is to describe the effects of AKB-9778 therapy 
on the solid tumour vasculature, tumour growth, and metastasis.  We 
hypothesized that as an activator of endothelial Tie-2 signaling, AKB-9778 might 
promote the development of a more mature, stable, functionally normalized 
vasculature within solid tumours – mitigating some of the adverse consequences 
associated with vessel abnormalities.   We specifically explored this in three 
settings: i) the earliest phases of tumour growth when Tie-2 deactivation 
promotes the onset of sprouting angiogenesis; ii) the earliest stages of metastatic 
colonization, with Tie-2 deactivation facilitates circulating tumour cells’ 
extravasation into distant organs; and iii) during the growth of established primary 
tumours, where vascular immaturity promotes tumour hypoxia and impairs the 
response to concomitantly administered cytotoxic therapies. 
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2 Chapter Two: Materials and Methods 
2.1 In vitro and molecular biology studies 
2.1.1 Cell lines and cell culture 
Human umbilical vein endothelial cells (HUVECs) were obtained from the Center 
for Vascular Excellence at the Brigham and Women’s Hospital (Boston, MA).  
HUVECs were received at passage zero, and all experiments were performed at 
passage numbers less than or equal to four.  HUVECs were cultured in 100mm 
tissue culture dishes coated with 0.1% gelatin (ATCC, Manassas, VA) in 
Endothelial Growth Medium (EGM, Lonza, Mapleton, IL) containing all 
manufacturer-supplied supplements.   
Human microvascular endothelial cells (HMVECs) were dermal microvascular 
endothelial cells purchased from Lonza (CC-2811 line) and were cultured in EGM 
with all manufacturer supplements on tissue culture dishes coated with 0.1% 
gelatin. 
The 4T1 murine mammary carcinoma line was purchased from ATCC and was 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, L-
glutamine, and sodium pyruvate (Cellgro, Manassas, VA), supplemented with 
10% fetal bovine serum (FBS)  (Sigma-Aldrich, St Louis, MO) and 1% MEM non-
essential amino acids (Invitrogen, Grand Island, NY).  The E0771 murine 
mammary carcinoma cell line was originally established by Dr Sirotnak (Memorial 
Sloan Kettering Cancer Center, New York) and were provided as a generous gift 
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by Dr Mihich (Roswell Park Cancer Institute, Buffalo, NY). E0771 was cultured in 
DMEM (ATCC) supplemented with 10% FBS and 1% HEPES buffer (Invitrogen).  
The 4T1 and E0771 cell lines were subcultured upon reaching 70-80% 
confluence at a ratio of 1:5.   
The MMTV-PyVT tumour cell line was derived as follows: spontaneously arising 
mammary tumours were resected from FVB/N-Tg(MMTV-PyVT) 634Mul/J mice 
(Jackson Laboratories, Bar Harbor, ME).  Tumours were cut into 1mm pieces 
under sterile conditions, and then digested at 37oC for 45 min in DMEM 
containing 10% fetal bovine serum, collagenase type 1A (1500 U/ml), 
hyaluronidase (1000 U/ml) and DNase (2 mg/ml) (all from Sigma). The digestion 
mixtures were filtered through 70 µm cell strainers. Cells were then cultured in 
DMEM media containing 10% fetal bovine serum and passaged ten times, until a 
homogenous tumour cell population was obtained.  
Human Embryonic Kidney (HEK) 293T cells were utilized for generation of 
lentiviral particles, were purchased from ATCC, and were cultured in DMEM with 
10% FBS.  
All cells were incubated continuously at 37oC in a humidified incubator with 5% 
carbon dioxide, and cell manipulation was performed under sterile conditions in a 
biosafety hood.   
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2.1.2 In vitro studies of AKB-9778 using endothelial cell lines 
The vascular-endothelial protein tyrosine phosphatase inhibitor AKB-9778 was 
provided under a Material Transfer Agreement with Akebia Therapeutics 
(Cincinatti, OH), the manufacturer of this compound.  For in vitro experiments, 
AKB-9778 was dissolved in a sterile solution of 5% dextrose.    
HUVECs or HMVECs were grown to confluence in 100mm cell culture dishes 
pre-coated with 0.1% gelatin.  Media was refreshed, AKB-9778 was added 
directly to the medium at a concentration of 10µM.  Cells were then incubated in 
AKB-9778 for varying lengths of time, as indicated within each experiment.  
When indicated, recombinant human angiopoietin-1 (500ng/mL, R&D Systems, 
Minneapolis, MN) and/or recombinant human angiopoietin-2 (500ng/mL, R&D 
Systems) was also added to the cell culture medium.  For angiopoietin-1 
treatment of cells, a mouse anti-polyHistidine monoclonal antibody (5 mg/mL, 
R&D Systems) was added with Ang-1 to facilitate multimerization (Kim et al., 
2005).   
After treatment, media was aspirated and cell dishes placed immediately on ice. 
Cells were then washed with ice-cold phosphate-buffered saline (PBS) and then 
lysed with RIPA buffer (Boston Bioproducts, Ashland, MA) supplemented with 
protease inhibitors (Complete Ultra, Roche, Indianopolis, IN) and phosphatase 
inhibitors (Phostop, Roche). Cell lysates were sonicated at 4ºC for 20 minutes 
and then centrifuged at 4ºC at 25,000xg for 20 minutes.  The supernatant was 
then collected, and the lysate protein concentration was determined using the 
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Bradford Quick Start Protein Assay Kit (Bio-Rad, Hercules, CA).  Lysates were 
then diluted to a final concentration of 1ug/uL in RIPA buffer and a 4X sodium 
dodecyl sulfate buffer (Boston Bioproducts), before denaturing at 95oC for 5 
minutes.  Denatured lysates were then subjected to Western Blotting as 
described below. 
2.1.3 Immunoprecipitation 
To assess tyrosine phosphorylation of Tie-2, VE-Cadherin, and plakoglobin in 
both endothelial cell lines and murine tissue, protein lysates were subject to 
immunoprecipitation of the protein in question prior to blotting with an anti-
phosphotyrosine antibody.   
Cell lysates were prepared as described above.  Protein lysates from murine 
tissue was obtained by cutting the tissue into 1-2mm pieces on ice, before 
immediately homogenizing the tissue in RIPA buffer containing protease and 
phosphatase inhibitors, sonicating the resultant lysate at 4oC for 20 minutes, and 
then centrifuging the lysate at 25,000xg for 20 minutes at 4oC. 
The primary immunoprecipitating antibody was then added to 200uL of the 
protein lysate.  Antibodies used for immunopreciptation were as follows: 
Antibody Manufacturer Concentration Catalog Number 
Tie-2 Santa Cruz 
Biotechnology (Santa 
Cruz, CA) 
1:50 sc-324 
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VE-
Cadherin 
Abcam (Cambridge, MA) 1:50 ab7047 
Plakoglobin Cell Signaling (Beverley, 
MA) 
1:100 2309 
 
The antibody-lysate mixture was then incubated with gentle rocking overnight at 
4oC.  The following day, 20uL of a fifty percent slurry of Protein A Sepharose 
beads (GE Healthcare Lifesciences, Pittsburgh, PA) was added and the mixture 
was incubated with gentle rocking at 4oC for 3h.  Samples were then centrifuged 
for 30 seconds at 4oC, and then washed five times with 500uL of RIPA buffer.  
After the fifth wash, the bead pellet was resuspended in 20uL of 3X SDS buffer, 
vortexed, and then microcentrifuged for 30 seconds.  Samples were then boiled 
at 95oC for 5 minutes, and microcentrifuged at 14,000g for 1 minute.  The 
supernatant was aspirated and subjected to Western Blotting for phosphorylated 
tyrosine residues as described below.   
2.1.4 Western Blotting 
Western Blots to assay protein and phospho-protein levels were performed using 
the Bio-Rad Mini Trans-Blot Cell, according to manufacturer’s instructions.  
Protein lysates were prepared and denatured as described above.  40ug of 
lysate (or the entire sample in the case of immunopreciptated proteins) was 
loaded into a polyacrylamide gel containing a percentage of acrylamide suitable 
for detecting the protein of interest (according to size).  Electrophoresis was 
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performed at 80 volts until lysate was seen to have entered the separating gel, at 
which time the voltage was increased to 100V. 
At completion of gel electrophoresis, protein was transferred to a nitrocellulose 
membrane at 4oC, using a Tris-glycine transfer buffer supplemented with 20% 
methanol.  Transfer was performed under a fixed voltage of 100V for 90 minutes.  
Membranes were washed in Tris-buffered saline (TBS) three times for five 
minutes, and then blocked in a solution of 5% dry non-fat milk (BioRad) in TBS 
for 1h at room temperature, with gentle rocking. 
Membranes were then washed again in TBS three times for five minutes, before 
being incubated in primary antibody overnight at 4oC, with gentle rocking.  All 
primary antibodies were prepared in a solution of 5% bovine serum albumin 
(BSA) in TBS supplemented with Tween-20 at 0.05% (TBST).  The primary 
antibodies used are listed below: 
Antibody Manufacturer Concentration Catalog Number 
Beta-tubulin Millipore (Billerica, MA) 1:2000 05-661 
Phospho-
tyrosine 
Millipore (Billerica, MA) 1:100 05-321 
Tie-2 Santa Cruz 
Biotechnology 
1:500 sc-324 
p-AKT (ser 473) Cell Signaling  1:1000 9271 
Total AKT Cell Signaling 1:1000 9272 
p-eNOS 
(ser1177) 
Abcam 1:1000 ab75639 
p-eNOS 
(Thr495) 
Cell Signaling 1:1000 9574 
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Total eNOS Abcam 1:1000 ab5589 
VE-Cadherin Abcam 1:500 ab7047 
Plakoglobin Cell Signaling 1:1000 2309 
Na-K-ATPase 
α1 isoform 
Cell Signaling 1:1000 3010 
 
The following day, membranes were washed in TBST three times for ten 
minutes, before incubation in secondary antibody for 1h at room temperature.   
Secondary antibodies for Western Blotting included anti-rabbit HRP (Cell 
Signaling) and anti-mouse HRP (GE Healthcare), and were suspended in a 
solution of 1% dry non-fat milk and 5% BSA in TBST.  Membranes were then 
washed three times for 10 minutes in TBS, and then incubated in the 
chemiluminescent ECL Plus Substrate (Thermo Scientific, Rockford IL) and 
developed in a dark room onto CL-XPosure Film (Thermo Scientific). 
2.1.5 Lentiviral production and infection of endothelial cells 
For gene silencing of Tie-2 in HUVECs, a lentiviral target gene set to TEK 
(Accessions NM_000459, AB208796, BC035514, and L06139) was purchased 
from Thermo Scientific and screened for Tie-2 silencing efficiency. Lentiviral 
particles were generated by co-transfection of pLKO.1-shTEK (10ug), pDelta8.9 
(5ug) and pVSVG (1ug) plasmids into 100mm dishes of HEK293T cells at 80% 
confluency. Transfection was performed using the Fugene-6 transfection reagent 
(Roche) according to manufacturer’s instructions, using a Fugene:pLKO.1-shTEK 
ratio of 3:1. HEK293T cell supernatant containing lentivirus was collected at 24 
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and 48h post-transfection, filtered through a 0.25um filter, and applied directly to 
low passage HUVECs at 70% confluence in 6 well plates, together with 
polybrene at a concentration of 8ug/mL. HUVECs were transduced for 24 h after 
which they were subjected to antibiotic selection with 2ug/ml puromycin for an 
additional 24-48h prior to seeding for indicated experiments.  The silencing 
efficiency of TEK was determined in primary endothelial cells by western blotting, 
and clone ID TRCN0000000415 was chosen for these studies. Lentiviral particles 
containing a scrambled shRNA sequence were used as a control (Sigma).  
2.1.6 Fractionation of cells into membranous and non-membranous 
compartments 
For experiments quantifying the amount of membranous versus non-
membranous VE-Cadherin in HUVECs, cells were lysed and processed using the 
Mem-PER Plus Membrane Protein Extraction Kit (Thermo Scientific).  This kit 
contains a cell wash solution, permeabilization buffer, and solubilization buffer 
and uses a mild detergent-based selective extraction protocol.  Cells are first 
permeabilized with a mild detergent, allowing the release of soluble cytosolic 
proteins, after which a second detergent solubilizes membrane proteins. 
Membrane proteins with one or two transmembrane domains are typically 
extracted with an efficiency of up to 90%, and cross-contamination of cytosolic 
proteins into the membrane fraction is usually less than 10%. 
HUVEC membrane and non-membrane fractions were prepared according to 
manufacturer’s instructions. 
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2.1.7 In vitro detection of nitric oxide production in HUVECs using DAF-2 
DA 
4,5-diaminofluorescein diacetate (DAF-2 DA) stock solution (5mM in DMSO) 
(Enzo Life Sciences Inc., Farmingdale, NY) was aliquoted and stored at -20oC in 
darkness under inert gas. The DAF-2 DA working dilution was prepared just 
before use. HUVECs were grown to confluence in EGM (with all manufacturer-
supplied supplements) on gelatin-coated and 0.5% glutaraldehyde cross-linked 
8-chamber culture slides (BD Biosciences). After washing with PBS, medium was 
changed to phenol red-free endothelial growth medium (Lonza) with 
manufacturer-supplied supplements and 0.5mM L-arginine (adjusted to pH 7.4). 
After 105 minutes, 100uM NG-Monomethyl-L-arginine (L-NMMA, Sigma-Aldrich) 
was added to indicated wells for 15 min, followed by a PBS wash. HUVECs were 
then loaded with 10 µM DAF-2 DA in HEPES buffered saline (pH 7.4) for 45 min 
at 37oC in darkness, with or without 16uM AKB-9778. 100 µM L-NMMA was 
again added for the negative controls. Cells were then washed with PBS, 
incubated with fresh phenol red free EGM (with manufacturer-supplied 
supplements) for 30 min at 37oC, PBS washed, fixed with 4% formaldehyde for 5 
min and mounted with Vectashield Mounting Medium for fluorescence with DAPI 
(Vector Laboratories Inc., Burlingame, CA).  Cells were imaged using an 
Olympus Fluoview FV 1000 confocal microscope and nitric oxide (NO) 
production measured by the ratio of FITC signal to DAPI signal, quantified using 
the ImageJ image analysis software (National Institutes of Health, Bethesda, 
MD). 
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2.2 Zebrafish studies 
2.2.1 Embryonic angiogenesis assays 
Flk-1:GFP transgenic zebrafish were obtained from the Cardiovascular Research 
Center, Massachusetts General Hospital (Charlestown, MA). Fertilized eggs 
were incubated either in E3 fish water (control) or E3 fish water supplemented 
with AKB-9778 (dissolved in DMSO) at the concentrations indicated. E3 fish 
water was made as a 60x stock solution (34.4 g NaCl, 1.52 g KCl, 5.8 g 
CaCl2.2H2O, 9.8 g MgSO4.7H2O, made up to 2L with 18 mOhm double distilled 
water.  The final DMSO concentration in both control and treatment groups in the 
fish water was 1%.  Embryos were examined under an epifluorescent 
stereomicroscope at 48h post-fertilization. Digital images were obtained and then 
analyzed by manually counting the number of intersegmental vessels seen to 
reach the dorsal longitudinal anastomotic vessel (DLAV) in each embryo.  
2.2.2 Zebrafish xenograft assays 
Fertilized Flk-1:GFP transgenic zebrafish eggs were incubated at 28ºC for 24h in 
E3 fish water. At 24h post-fertilization, embryos were manually dechorionated 
with forceps and then placed into incubation medium containing 75uM 
propythiouracil (Sigma) in E3 fish water. At 48h post-fertilization, embryos were 
anesthetized with 0.02mg/mL tricane and then aligned in the lateral decubitus 
position on an agarose-modified Petri dish. 4T1-dsRed tumour cells were 
suspended in growth factor reduced Matrigel (BD Bioscience, San Jose, CA) 
diluted with PBS to a protein concentration of 8.25mg/mL, at a density of 5x106 
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cells/60uL Matrigel. A hand-pulled borosilicate needle was loaded with 10uL of 
tumour cell suspension. Using a microinjector under 50 X stereomicroscopic 
magnification, the needle tip was introduced into the perivitelline space in 
proximity to the developing sub-intestinal vein plexus. 10nL of tumour cell 
suspension was injected per embryo. The injections were performed by Dr Brian 
Walcott (Massachusetts General Hospital, MA).  Embryos were then recovered in 
fresh E3 fish water for 1h and then either maintained in E3 fish water or in AKB-
9778 (100mM in DMSO). Embryos were fixed with 4% paraformaldehyde in PBS 
for 2h, 48h post-xenografting. Tumour neovascularization was examined using a 
confocal microscope – axial sections were obtained through the entire tumour 
mass and five sections analyzed per embryo. Neovascularization was quantified 
by the ratio of GFP-positive area (endothelial cells) to dsRed positive area 
(tumour mass) using ImageJ software. 
 
2.3 Murine studies 
All animal procedures were performed following the guidelines of Public Health 
Service Policy on Humane Care of Laboratory Animals and approved by the 
Institutional Animal Care and Use Committee of the Massachusetts General 
Hospital, Boston MA. Mice were bred and maintained in a gnotobiotic (defined 
flora) animal facility in the Edwin L. Steele Laboratory within the Massachusetts 
General Hospital. NCr/Sed Nude mice (nu/nu), C57BL6/J mice, and FVB/N-
Tg(MMTV-PyVT)634Mul/J mice were originally obtained from Jackson 
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Laboratories (Bar Harbor, ME). FVB/N mice originally were obtained from 
Taconic Farms (FVB/NTac; Germantown, NY) in July 1999. Nos3-/- (eNOS-/-) 
mice were obtained from Dr. Paul Huang (Massachusetts General Hospital, 
Boston MA).  
2.3.1 Murine models of mammary carcinoma 
To establish 4T1 primary tumours, 4T1 tumour cells were harvested at 80% 
confluence, and resuspended in PBS. Mice were first anaesthetized by 
intraperitoneal injection of ketamine (150mg/kg) and xylazine (10mg/kg).  For 
early tumour growth studies, 2 x 104 4T1 cells (suspended in 50uL of PBS) were 
injected into the left third mammary fat pad of female nude mice aged 6-8 weeks.  
For studies of established tumours, 5 x 104 tumour cells into the left third 
mammary fat pad of female nude mice aged 6-8 weeks.  
To establish E0771 primary tumours, E0771 tumour cells were harvested at 80% 
confluence, resuspended in PBS, and injected into the left third mammary fat pad 
of anaesthetized female C57BL6/J mice aged 6-8 weeks (2 x 105 tumour cells in 
50uL of PBS).  
The P0008 mammary carcinoma was derived in the laboratory of Rakesh K. Jain 
from a spontaneously occurring mammary carcinoma in a female mouse with an 
FVB/N background (Huang et al., 2008).  In the present study, P0008 tumours 
were established by implanting 1-2mm viable fragments of tumour tissue from 
P0008 tumour-bearing FVB/N mice directly into the left third mammary fat pads 
of 6-8 week old female FVB/N mice. Mice were first anaesthetized with ketamine 
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and xylazine, and then shaved to expose the skin around the left third nipple.  A 
3-4mm cutaneous incision was made 5mm inferior to the nipple, and a small 
tumour fragment inserted through this incision into a subcutaneous pocket 
directly below the nipple.  The incision was then closed with a single nylon 
suture.  
For MMTV-PyVT tumour growth experiments, we monitored MMTV-PyVT mice 
for the appearance of spontaneous tumours and commenced treatment when the 
largest palpable tumour reached 3mm diameter. Although MMTV-PyVT mice 
develop multiple spontaneous tumors, only this tumour was measured and 
analyzed during treatment.  
Tumours were measured daily with calipers except where otherwise specified. 
Tumour volume was calculated as Volume = 4/3 x π x (long axis/2) x (short 
axis/2)2.  
2.3.2 Drug treatment of mice 
AKB-9778 was injected at a dose 40 mg/kg subcutaneously every 12h.  AKB-
9778 was dissolved in 5% dextrose, except where otherwise specified. Control 
vehicle was the same volume of 5% dextrose. Doxorubicin was administered at 
2.5 mg/kg via intraperitoneal injection every 72h.  
2.3.3 Measurement of tumour hypoxia 
To assess hypoxia, tumour-bearing mice were injected with pimonidazole 
hydrochloride (Hypoxyprobe, Burlington MA) at a dose of 60mg/kg 
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intraperitoneally, 1h before sacrifice. At the time of sacrifice, mice were 
anaesthetized with ketamine and xylazine, after which tumours were surgically 
excised and fixed according to protocols described below. 20um thick frozen 
sections were prepared, and stained with the Hypoxyprobe monoclonal antibody 
using a mouse-on-mouse staining kit (Vector Laboratories, Burlingame, CA). 
Sections were analyzed using confocal microscopy as described in section 2.5. 
2.3.4 Measurement of tumour perfusion 
To assess perfusion, 100mg of biotinylated tomato lectin (Vector Laboratories) 
was injected into the lateral tail vein of anesthetized, tumour-bearing mice 5 
minutes before sacrifice. After 5 minutes, tumours were excised, fixed, and 20um 
frozen sections were prepared.  Immunofluorescent staining for the presence of 
biotinylated lectin was then performed using the AlexaFluor 546-streptavidin 
conjugate (Invitrogen).  Details of immunofluorescent staining techniques are 
provided below. 
2.3.5 Intravital microscopy and assessment of tumour vessel permeability in 
vivo 
Tumours were implanted in the mammary fat pad of female mice and a 
mammary fat pad chamber placed over the tumour once it reached diameter 2-
3mm, as previously described (Vakoc et al., 2009). To measure effective 
vascular permeability, mice were anesthetized with inhaled isoflurane and 
injected via retro-orbital injection with tetramethylrhodamine labeled BSA 
(Invitrogen) for baseline images and AlexaFluor-647 BSA (Invitrogen) at the post-
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treatment time point (to avoid inadvertent imaging of tetramthylrhodamine-BSA at 
the second time point). At each time point, two distinct regions within the tumour 
were selected and a 200um image stack recording BSA fluorescence was taken 
through each region every ten minutes for 1h, using a multiphoton laser-scanning 
microscope. The analysis approach involved three-dimensional vessel tracing to 
create vessel metrics and a three-dimensional map of voxel intensity versus 
distance to the nearest vessel over time. Images were also corrected for sample 
movement over time with three-dimensional image registration. The normalized 
transvascular flux was calculated using 
 
where Jt is the transvascular flux, Sv the vessel surface area, Cv the 
concentration of the probe in the vessel, C the concentration of the probe 
immediately extravascular, Peff the effective permeability, t time after the initial 
image, r the distance from the vessel central axis, and R the vessel radius at that 
point along the vessel. The calculation was made as an average over the entire 
imaged volume for each tumour. 
Optical frequency domain imaging (OFDI) of tumour perfusion was performed 
using orthotopic 4T1 carcinomas under mammary fat pad windows, as previously 
described (Vakoc et al, 2009).  Briefly, tumours were implanted in the mammary 
fat pad of female mice as described above, and a mammary fat pad chamber 
placed over the tumour once it reached diameter 2-3mm.  The OFDI microscope 
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and image analysis were built and designed at the Wellman Center for 
Photomedicine at the Massachusetts General Hospital.  Pre-designed software 
and image processing algorithms were available at the time that OFDI 
experiments were performed, and are the subject of a previously published report 
(Vakoc et al., 2009). 
2.3.6 Metastasis assays 
Studies of spontaneous pulmonary metastasis were performed using the 4T1 
tumour model in female nude mice, designed to model the effects of adjuvant 
therapy.  Tumours were implanted into the mammary fat pad as described 
above.  
It was initially determined through a series of pilot experiments that 
micrometastatic tumour cells were first consistently apparent within the lungs of 
4T1 tumour-bearing mice once primary tumours reached 5mm in diameter.  In 
experiments presented here, tumours were therefore resected from the 
mammary fat pad once they reached a diameter of 5mm.  This was performed as 
a survival surgery: mice were anaesthetized with ketamine and xylazine, and the 
region around the tumour cleaned with 70% ethanol.  The mammary tumour was 
then gently lifted away from the thoracic cage with sterile forceps, and the skin 
around the tumour was cut with surgical scissors until the entire tumour was 
excised.  The resultant skin deficit was closed with nylon sutures.   
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24h after surgery, therapy was begun with either AKB-9778 or control vehicle, 
and the effects of therapy on the progression of lung metastases as well as 
metastases in other organs were studied.  
Mice were sacrificed at a series of different time points: examination of the lungs 
after two weeks of therapy was performed to study metastases histologically: 
lungs were resected, tissue was fixed in 4% formaldehyde, and 5um paraffin-
embedded sections were prepared at 100um intervals throughout all lobes of all 
lungs. These were stained with hematoxylin and eosin and metastases identified 
and counted by a trained pathologist. Metastases were photographed digitally 
and their area determined using ImageJ software. 
To examine for macroscopic metastases, lungs were resected after 3 weeks of 
treatment and immersed in Bouin’s solution (Sigma). After 24h, tissues were 
examined under a stereomicroscope at 4x magnification and all metastases 
visible on the lung surface were counted. Metastases were seen clearly as white 
nodules on the background of yellow normal lung tissue.  In these studies, full 
necropsy was also performed on all mice, and metastases macroscopically 
evident in liver, bone, lymph nodes, or soft tissues were documented.  
For survival studies, mice were treated either with doxorubicin chemotherapy 
alone after resection of primary tumours (2.5mg/kg intraperitoneally every 72h) or 
with doxorubicin in addition to AKB-9778.  Mice were sacrificed by carbon dioxide 
inhalation if they appeared moribund, were unable to eat or drink, or had lost 
over 10% of bodyweight. 
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For experimental micrometastasis assays, 4T1 (1 x 106), E0771 (5 x 105), or 
MMTV-PyVT (5x105) tumour cells were injected into the tail vein of nude, 
C57BL/J, and FVB/N mice respectively, and treatment with AKB-9778 or control 
vehicle was commenced 12h later. Treatment was continued for 5 days for the 
E0771 and MMTV-PyVT experiments, and for 8 days for the 4T1 experiments.  
At the end of treatment, the lungs of anesthetized mice were fixed by intra-
tracheal instillation of 4% paraformaldehyde. A minimum of 3 representative 5uM 
sections (at least 100uM apart) through each lobe of each lung were stained with 
hematoxylin and eosin and analyzed by two investigators including a trained 
pathologist. The number of metastatic foci was counted for each lung section. 
Each tumour focus was graded as intra- or extravascular and number of cell 
nuclei visible at 400x magnification in each focus was counted as a marker of 
tumour size.  
2.3.7 In vivo assays of Tie-2 phosphorylation 
For in vivo assessment of Tie-2 phosphorylation, mice received a single dose of 
AKB-9778 40 mg/kg in 5% dextrose intravenously. Lungs or tumours were 
resected 1h later and immediately frozen in liquid nitrogen. Tissues were later 
homogenized in RIPA buffer supplemented with protease inhibitors and 
phosphatase inhibitors (as described in section 2.1.2) before immunoprecipitation 
for Tie-2 and western blotting for phospho-tyrosine as described above.  
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2.3.8 Delivery of external beam radiotherapy to murine mammary tumours 
Tumour-bearing mice were anesthetized with a combination of ketamine and 
xylazine via intraperitoneal injection. Mice were secured in the supine position on 
a supportive plastic platform using adhesive tape. A 15mm lead collimator of 
6mm thickness was placed over the mammary fat pad tumour, and the mouse 
placed into the irradiator (XRAD 320, Precision X-Ray Inc., North Branford, CT). 
Radiation was directed at 3.52 Gy/min to a total of 20 Gy through the collimator 
aperture.  
2.3.9 Miles assay  
The Miles assay was used to measure changes in the permeability of normal 
murine skin vessels in response to AKB-9778 therapy.  Mice were treated with 
AKB-9778 or vehicle control for 24h. One hour after the last dose, mice were 
anesthetized with ketamine/xylazine at doses described above, and Evan’s Blue 
dye (Sigma) was injected intravenously via the lateral tail vein (100uL of a 1% 
solution in PBS). Thirty minutes later, bilateral 7mm skin punch biopsies were 
taken and snap frozen in liquid nitrogen. At the time of analysis, tissue was 
thawed to room temperature, weighed, and incubated in 1mL of formamide 
overnight at 55oC. Evan’s blue content was then assessed by spectrophotometric 
measurement of formamide containing eluted Evan’s Blue at a wavelength of 
620nm, and was normalized for the weight of each tissue fragment analyzed. 
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2.3.10 Measurement of mouse blood pressure 
Mice were anaesthetized with ketamine/xylazine (dose normalized to body 
weight) and positioned in the supine position. Cannulation of the carotid artery 
was performed as previously described (Duyverman et al., 2012) by Ms Sylvie 
Roberge (Massachusetts General Hospital, MA). The arterial pressure waveform 
was obtained by connecting a carotid artery cannula to a pressure transducer via 
heparin-filled PE10 tubing. Mean arterial pressure was calculated as MAP = 
((diastolic BP x 2) + systolic BP))/3. 
2.4 Tissue processing, immunofluorescence, and 
immunohistochemistry 
2.4.1 Fixation and processing of tissues for histologic analysis 
Excised murine tissue (mammary tumours, lungs) was fixed by immersion in 4% 
formaldehyde in PBS (time of fixation (h) = diameter of tissue fragment (mm)/2). 
 To prepare tissue for frozen sections, this was followed by 3 washes in PBS and 
then dehydration in 30% sucrose in PBS overnight at 4ºC. Tissue was 
subsequently mounted in freezing media (OCT, Tissue-Tek, Torrance, CA). 
20um frozen sections were prepared for immunofluorescent staining.  To prepare 
tissue for paraffin embedding, it was washed three times after fixation and then 
stored in 70% ethanol.  Tissue processing, cassetting, and embedding was then 
performed by the Department of Pathology at the Massachusetts General 
Hospital. 
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2.4.2 Immunofluorescent staining of frozen tissue sections 
20um frozen sections were cut, placed onto glass microscope slides, and stored 
at -80oC.  At the time of staining, sections were air-dried at room temperature for 
1h, post-fixed in acetone at -20ºC for 5 minutes, and then washed in PBS. Five 
percent normal horse serum (Jackson Immunoresearch, West Grove, PA) was 
used for blocking (1h at room temperature) and for diluting primary antibody 
(overnight at 4ºC) and secondary antibody (1h at room temperature in darkness).  
Primary antibodies for immunofluorescent staining were as follows: 
Antibody Manufacturer Concentration Catalog Number 
CD31 Millipore  1:200 1398 
NG2 Millipore  1:1000 5320 
Desmin R&D Systems 1:50 AF3844 
VE-Cadherin Abcam 1:50 ab7047 
 
Secondary antibodies for immunofluorescence (Cy3-Donkey anti-Rabbit, 
DyLight-649–Goat anti-Armenian Hamster, and Cy3-Donkey anti-Goat) were 
purchased from Jackson Immunoresearch and used at a concentration of 1:200.  
After incubation in secondary antibody, sections were washed three times in PBS 
and then mounted with 4'-6-diamidino-2-phenylindole (DAPI)–containing 
mounting media (Vectashield, VectorLabs, Burlingame, CA) for confocal 
microscopy. 
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2.4.3 Immunohistochemical staining of paraffin-embedded tissue sections 
5um sections were cut from tissue previously fixed and embedded in paraffin 
blocks.  Slides were then deparaffinized by washing sequentially in 100% xylene, 
100% ethanol, 95% ethanol, 70% ethanol, and then demineralized water (two 
five minute washes in each solution).  Slides were then subject to antigen 
retrieval using a citric acid based antigen unmasking solution (Vector 
Laboratories) in a conventional microwave.  After cooling in antigen retrieval 
solution for 20 minutes, slides were washed twice in PBS (3 minutes each), then 
blocked in 5% horse serum for 1h at room temperature.  Slides were then 
incubated in primary antibody overnight at 4oC (Collagen IV antibody, Abcam 
catalog number ab6586 at concentration 1:1000).  The following day slides were 
washed three times in PBS, and then soaked in 3% hydrogen peroxide for 10 
minutes to quench endogenous peroxidase activity.  After further washes in PBS, 
slides were incubated in secondary antibody (Biotin-SP-AffiniPure Donkey Anti-
Rabbit IgG, Jackson Immunoresearch catalog number 711-065-152 at 
concentration 1:200) for 1h at room temperature.  After three further PBS 
washes, slides were developed using a standard streptavidin-biotin-horseradish 
peroxidase-diaminobenzidine protocol (VECTASTAIN Elite ABC Kit, Vector 
Laboratories, and Immpact Kit Dab, Thermo Fisher Scientific, according to 
manufacturer’s instructions).  The peroxidase reaction was stopped by soaking 
slides in demineralized water, before counterstaining with hematoxylin, 
dehydration to xylene, and application of mounting media (Permount, Thermo 
Fisher Scientific) and coverslips. 
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2.5 Confocal microscopy and image analysis 
For analysis of vascular parameters in frozen sections stained with 
immunofluorescence, an Olympus FV1000 confocal microscope was used. Multi-
area time-lapse imaging was performed such that the entire tumour cross-section 
was visualized over its entire thickness, and the compiled three-dimensional 
image stack was used included for image analysis. Quantification of the stained 
area was performed using an in-house segmentation algorithm (MATLAB, The 
Mathworks, Natick, MA). Analysis of vessel diameter and vessel density was 
performed using an in-house MATLAB algorithm which skeletonized the entire 
tumour vasculature before determining the mean diameter of each vessel 
segment and hence the mean vessel diameter for each tumour. Analysis of 
pericyte-endothelial cell proximity was performed by fitting the intensity profile 
around the vessels (determined by CD31 staining) to an exponential function (I = 
Ae-x/L + C), where I = pixel intensity, x = distance from vessels (1 to 10um), and L 
= characteristic length.  
2.6 Statistical Methods 
All animal experiments were designed after consultation with a statistician.  
Statistical analysis was performed using GraphPad Prism Software version 5.0 
(GraphPad Software, Inc). Unless otherwise specified, statistical comparisons 
between experimental groups were made using the unpaired t-test. The chi-
squared and Fisher’s exact tests were used as indicated to compare the relative 
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distribution of metastatic events (by size or location). Repeated measures one-
way analysis of variance (ANOVA) was used for the analysis of primary tumour 
growth curves. Survival analysis was performed using the Log-rank (Mantel Cox) 
test. All statistical tests were two-sided. Differences were considered statistically 
significant at a p value less than 0.05. 
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3 Chapter Three: The effects of AKB-9778 on Tie-2 
activation and endothelial cell junctional proteins 
3.1 The effects of AKB-9778 on endothelial cell Tie-2 signaling in vitro 
Data provided by Akebia Therapeutics (manufacturers of AKB-9778, 
unpublished) suggest that AKB-9778 is a potent and specific inhibitor of the 
Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP).  Given that VE-
PTP is known to dephosphorylate (and hence inactivate) the endothelial cell (EC) 
Tie-2 kinase, the capacity for AKB-9778 to activate Tie-2 signaling in ECs was 
determined. 
Human umbilical vein endothelial cells (HUVECs) and human microvascular 
endothelial cells (HMVECs) were treated with AKB-9778 in vitro for 15 or 30 
minutes.  In both cases, immunoprecipated Tie-2 from cell lysates showed a 
marked increase in tyrosine phosphorylation after AKB-9778 exposure (Fig 2 & 
3).  
To determine if this increase in Tie-2 phosphorylation was associated with 
activation of Tie-2 signaling, assays for changes in the phosphorylation of known 
effector molecules lying downstream of Tie-2 in EC’s were performed.  In both 
HUVECs (Fig 4) and HMVECs (Fig 5), short-term exposure to AKB-9778 led to a 
rapid and potent increase in phosphorylation of AKT (serine 473 residue) and 
endothelial nitric oxide synthase (eNOS, serine 1177 residue).   These results 
strongly suggest that AKB-9778 activates Tie-2 signaling within ECs. 
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Given that AKB-9778 is a phosphatase inhibitor, it is possible that the changes 
observed above could be the result of non-specific EC phosphatase inhibition 
rather than a specific effect of VE-PTP inhibition and thus Tie-2 activation.  To 
address this possibility, a Tie2-shRNA construct to knockdown the expression of 
Tie-2 within HUVECs was used (Figure 6, left). Tie-2-shRNA HUVECs and 
scrambled-shRNA HUVECs were treated with AKB-9778.  HUVECs with 
diminished Tie-2 expression showed a marked abrogation of AKT and eNOS 
phosphorylation in response to AKB-9778, establishing the target specificity of 
AKB-9778 (Figure 6, right). 
3.2 The effects of AKB-9778 on Tie-2 activation in vivo  
Tie-2 phosphorylation after AKB-9778 exposure in vivo was determined next.  
Female nude mice were injected with a single dose of AKB-9778 intravenously 
(IV), and the lungs removed after 1h.  Tie-2 was then immunoprecipitated from 
whole lung lysates, and blotted for phospho-tyrosine. AKB-9778 induced strong 
phosphorylation of Tie-2 tyrosine residues (Fig 7, left). The same experiment was 
repeated in female nude mice bearing orthotopic 4T1 mammary tumours. One 
hour after IV injection of AKB-9778, an increase in Tie-2 phosphorylation within 
tumour lysates was seen (Fig 7, right). 
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Figure 2: Tie-2 tyrosine phosphorylation in human umbilical vein 
endothelial cell (HUVEC) lysates after AKB-9778 treatment.  
Experiments were repeated in triplicate, with similar results (p-
Tyr:Tie2 band intensity ratio is 0.24, 0.88, and 0.84 for 0m, 15m, and 
30m respectively). 
 
Figure 3:  Tie-2 tyrosine phosphorylation in human microvascular 
endothelial cell (HMVEC) lysates after AKB-9778 treatment.  
Experiments were repeated in duplicate, with similar results (p-Tyr:Tie2 
band intensity ratio is 0.24, 0.88, and 0.84 for 0m, 15m, and 30m 
respectively). 
 
Figure 4: Levels of phosphorylated AKT (ser 473), total AKT, phosphorylated eNOS (ser 1177), 
and total eNOS in HUVEC lysates after treatment with AKB-9778.  Experiments were repeated in 
triplicate, with similar results (Ratio of band intensities p-AKT:total AKT is 0.28, 0.30, 1.05, 1.13, 
1.47, and 0.91 for 0m, 5, 15m, 30m, 60m, and 120m respectively. Ratio of band intensities p-
eNOS:total eNOS is 0.38, 0.39, 1.05, 1.13, 1.47, and 0.91 for 0m, 5, 15m, 30m, 60m, and 120m 
respectively 
  70 
 
 
 
 
 
 
 
Figure 6: Left, Confirmation of TIE-2 knockdown after TIE-2 shRNA transduction to HUVECs 
(densitometry confirms knockdown of 75% at protein level). Right, Phosphorylated AKT (ser 473 
residue), total AKT, phosphorylated eNOS (ser 1177 residue), and total eNOS levels in HUVEC 
lysates or Tie2-shRNA HUVEC lysates after exposure in vitro to AKB-9778.  Experiments were 
repeated in triplicate, with similar results. 
 
Figure 5: Levels of phosphorylated AKT (Ser473), total AKT, phosphorylated eNOS (Ser1177), 
and total eNOS in HMVEC lysates after treatment with AKB-9778.  Experiments were repeated in 
duplicate, with similar results. 
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Figure 7: Left, Tie-2 tyrosine phosphorylation in murine whole lung lysates 1h after 
intravenous injection of AKB-9778 or control vehicle.  Experiment was repeated in duplicate, 
with similar results. Right, Tie-2 tyrosine phosphorylation in murine orthotopic 4T1 mammary 
carcinoma lysates 1h after intravenous injection of AKB-9778 or control vehicle. CT1 and 2, 
and AKB1, 2, and 3 represent tumor samples from individual mice from the same 
experiment.  Experiment was performed once only. 
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3.3 The impact of AKB-9778 Tie-2 activity in different ligand contexts  
The effect of Tie-2 ligands angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) 
upon AKB-9778-induced Tie-2 activation was next determined.  In vitro, Ang-1 
acts as a potent Tie-2 agonist and in keeping with this, was found to activate the 
Tie-2 pathway in HUVECs (Fig 8).  Ang-2 can demonstrate mixed 
agonistic/antagonistic effects on Tie-2, and in our experiments we found minimal 
change in Tie-2 signaling in HUVECs after Ang-2 treatment. Importantly, AKB-
9778 induced similar levels of Tie-2 pathway activation (measured by p-AKT and 
p-eNOS) in the presence of Ang-1, Ang-2, both, or neither (Fig 8).  This ligand-
independent activation of Tie-2 suggests that it could stimulate Tie-2 activity 
regardless of ligand levels in the local microenvironment. 
3.4 Effects of AKB-9778 on endothelial cell junctional proteins 
In addition to Tie-2, the EC-EC adhesion molecule VE-Cadherin has also been 
reported to interact with VE-PTP, either directly or indirectly though 
phosphorylation of plakoglobin (gamma-catenin).  Therefore, the effects of AKB-
9778 on VE-Cadherin and plakoglobin phosphorylation within HUVECs were 
examined.  AKB-9778 treatment of HUVECs induced tyrosine phosphorylation of 
both of these EC junctional proteins (Fig 9 a,b).  Importantly, AKB-9778 did not 
induce phosphorylation of serine residues on VE-Cadherin (a key determinant of 
VE-Cadherin internalization and degradation, Fig 9c).  Furthermore, the total 
amount of membrane-associated VE-Cadherin after AKB-9778 treatment did not 
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change, whether assessed by western blot of fractionated cell lysates (Fig 9d, f) 
or immunofluorescence (Fig 9e). 
 
Collectively the data presented in Chapter Three shows that AKB-9778 is a 
potent inhibitor of VE-PTP that induces Tie-2 activation in ECs in a ligand-
independent fashion.  Furthermore, although VE-Cadherin phosphorylation is 
also increased by AKB-9778, there is no change in VE-Cadherin subcellular 
localization. 
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Figure 8: Levels of phosphorylated AKT (ser 473), total AKT, phosphorylated eNOS (ser 1177), 
and total eNOS in HUVEC lysates after 30 minutes’ treatment with Ang-1, Ang-2, and/or AKB-
9778.  Experiments were performed in duplicate, with similar results. 
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Figure 9: a) Western blot for phospho-tyrosine and total plakoglobin levels in HUVEC lysates after 
immunoprecipation for plakoglobin. b) Western blot for phospho-tyrosine and total VE-Cadherin 
levels in HUVEC lysates after immunoprecipation for VE-Cadherin. c) Western blot for phospho-
serine and total VE-Cadherin levels in HUVEC lysates after immunoprecipation for VE-Cadherin 
(band densitometry ratios of p-ser:VE-Cad are 0.163, 0.276, and 0.142 for 0, 1, and 16h 
respectively). d) Confluent HUVECs were exposed to AKB-9778 in vitro for indicated time. 
Lysates were fractionated into cellular membrane and non-membrane fractions. Western blot 
shows total VE-Cadherin in membrane fraction (Na-K-ATPase as loading control). e) 
Immunofluorescence for VE-Cadherin in HUVECs after treatment with AKB-9778 over the same 
time course, scale bars 20 µm. f) Quantitative densitometry of Western blot in upper panel.  
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4 Chapter Four: The effects of AKB-9778 on embryonic 
angiogenesis  
VE-PTP null mice are embryonically lethal due to severe defects in angiogenesis 
attributed to Tie-2 hyperactivation (Baumer et al., 2006, Dominguez et al., 2007).  
Because the VE-PTP phosphatase domains of Danio rerio (zebrafish) and Mus 
musculus have high sequence homology, we evaluated the effects of AKB-9778 
on embryonic vessels in zebrafish. This was done in order to further characterize 
the activity of AKB-9778 as a VE-PTP inhibitor.  
4.1 Impact of AKB-9778 on embryonic angiogenesis in Danio rerio  
Flk1:GFP zebrafish demonstrate expression of green fluorescent protein (GFP) 
in endothelial cells, allowing clear visualization of blood vessels. Flk1:GFP 
zebrafish embryos were incubated in AKB-9778 and the developing vasculature 
was examined at 48h post-fertilization (hpf) under epifluorescence.  
AKB-9778 induced specific defects in embryonic angiogenesis using this model 
(Fig 10).  Of note, intersegmental vessels (ISVs) showed marked tortuosity and 
reduced sprouting.  Furthermore, many ISVs had failed to reach the dorsal 
longitudinal anastomotic vessel (DLAV) by 48hpf, indicating impaired 
angiogenesis (Fig 10, middle and lower panels).  When quantified, there was a 
statistically significant reduction in the number of ISVs making contact with the 
DLAV in the embryos incubated in AKB-9778 (Fig 11). 
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Figure 10: Representative epifluorescence micrographs of Flk-1:GFP zebrafish 
embryos treated with control vehicle (DMSO) (top panel) or AKB-9778 (middle 
panel) at 48h post-fertilization (hpf).  Lower panels (left and right) show high-
powered images of AKB-9778-treated embryos at 48 hpf.  [DA = dosal aorta; ISV 
= intersegmental vessel; DLAV = dorsal longitudinal anastomotic vessel].  Scale 
bars: top panel = 100µm; middle = 75µm; bottom panels = 50µm. 
 
 
Figure 11: Percentage of vessels that sprouted from the dorsal aorta to reach the dorsal 
longitudinal anastomotic vessel in zebrafish embryos treated with control vehicle (DMSO) or AKB-
9778 (*p < 0.0001 by Chi-squared test, n = 5-6 embryos per group). 
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4.2 Impact of AKB-9778 on angiogenesis in a Danio rerio xenograft 
model 
A previously reported assay of tumour angiogenesis using zebrafish embryos 
(Nicoli and Presta, 2007) was then utilized to study the effects of AKB-9778 upon 
early tumour angiogenesis (in the context of an embryonic system).   This assay 
was performed with the assistance of Dr Brian Walcott of the Massachusetts 
General Hospital, Boston MA (Fig 12).  Murine mammary carcinoma cells 
expressing the dsRed fluorescent protein (4T1-dsRed) were implanted into the 
avascular perivitelline space of Flk1:GFP zebrafish embryos at 48hpf.  Within 
48h of implantation, a small tumour mass was visible (Fig 12, left).  Using 
confocal microscopy, nascent vessels were observed sprouting into the tumour 
mass (Fig 12, centre).  The degree of tumour angiogenesis was determined by 
dividing the total GFP-positive area within the tumour by the total tumour area 
(Figure 12, right).   Consistent with the findings in the embryonic angiogenesis 
model, there was a reduction in the degree of tumour neoangiogenesis amongst 
those embryos incubated in AKB-9778 for 48h after tumour implantation (Figure 
13). 
Collectively, the data presented in Chapter Four show that as a VE-PTP inhibitor, 
AKB-9778 induces a failure of embryonic angiogenesis, akin to that previously 
reported in VE-PTP null mice.  Moreover, AKB-9778 hinders tumour 
angiogenesis in the zebrafish embryo tumour xenograft assay. 
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The remainder of this thesis pertains to the consequences of VE-PTP inhibition 
with AKB-9778 in an adult mammalian model organism (Mus musculus), with a 
specific focus on the solid tumour vasculature.   
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Figure 12: Xenograft tumour growth and vascularization in the zebrafish perivitelline 
space. Left, Confocal micrograph demonstrating growth of a 4T1-dsRed mammary carcinoma 
in the perivitelline space of a zebrafish embryo (white arrow indicates tumour, scale bar 270 
µm). Centre, High power confocal micrograph demonstrating neovascularization of a 4T1-
dsRed xenograft in a Flk-1:GFP zebrafish embryo. Nascent vessels (green) are indicated by 
white arrows (scale bar 50 µm). Right, Method for delineating tumour area for analysis of 
xenograft vessel density in zebrafish embryos. Area considered as “tumour area” is outlined by 
yellow-dashed line (scale bar 50 µm). 
 
  
Figure 13: Left, 4T1-dsRed mammary carcinomas growing in Flk-1:GFP zebrafish embryos 
treated with control vehicle (left panel) or AKB-9778 (right panel).  Right, Vessel density 
(determined as GFP-positive area/tumour area) from experiment in (c) (*p = 0.001 by t-test, 
n = 6 embryos per group.  Value for each embryo is determined as the mean of five 
individual micrographs taken throughout each tumour).   
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5 Chapter Five: The effects of AKB-9778 on murine 
mammary carcinoma 
5.1 The effects of AKB-9778 on the early stages of primary tumour 
angiogenesis and growth 
The effects of VE-PTP inhibition on the earliest phase of primary tumour 
development were studied next.  During this time, tumour cells typically co-opt 
normal host ECs (Holash et al., 1999), leading them to overexpress Ang-2 and 
VE-PTP (Holash et al., 1999, Dominguez et al., 2007).  This is in turn facilitates 
vascular destabilization, allowing for the onset of sprouting angiogenesis (Holash 
et al., 1999).  Furthermore, abrogation of Ang-2 activity has been shown to 
specifically slow this earlier phase of tumour development, related at least in part 
to the prevention of early vessel destabilization (Nasarre et al., 2009). 
5.1.1 Impact of AKB-9778 on the early phase of primary tumour growth 
4T1 murine mammary carcinoma cells were implanted orthotopically into the 
mammary fat pads of female nude mice, and VE-PTP inhibition with AKB-9778 
was initiated 24h later.  AKB-9778 delayed the early phase of solid tumour 
growth (Fig 14, left) but had no impact on the later phases of tumour growth.  
Similar results were seen using the E0771 mammary carcinoma model in 
syngeneic C57Bl6/J mice (Fig 14, right).  When growth curves from the 4T1 
experiment are re-plotted using a logarithmic scale on the y-axis, it is clear that 
differences in primary tumour size are exclusively due to a delay in the early 
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phase of tumour growth (Fig 15).  Of interest, these results mirror those seen 
when solid tumours are grown in Ang-2 deficient mice (Nasarre et al., 2009). 
Of note, VE-PTP gene expression was not detectable in either cell line by RT-
PCR, and AKB-9778 had virtually no cytotoxic effects on these cells in vitro (IC50 
>300µM), suggesting that the our observations were not caused by a direct effect 
of AKB-9778 on tumour cell growth. 
5.1.2 Impact of AKB-9778 upon vessel stability during early tumour growth 
The vasculature of treated and untreated mammary tumours during the early 
phase of tumour growth was next examined.  4T1 cells were implanted 
orthotopically as before and AKB-9778 or control vehicle treatment begun after 
24h. After 7-8 days (when tumour growth rates were discrepant, and tumour 
diameter was less than 1mm), tumours were resected and stained for NG2 (a 
marker of pericytes) and CD31 (a marker of ECs).  After image analysis, it was 
noted that AKB-9778 treated tumours showed a significantly higher degree of EC 
coverage by pericytes.  Furthermore, the mean distance between pericytes and 
EC’s was significantly reduced in AKB-9778 treated tumours (Fig 16, 17). 
Collectively, the data presented in section 5.1 shows that inhibition of VE-PTP 
hinders vascular destabilization during the early phase of tumour growth – 
evidenced by enhanced vascular pericyte coverage.  This is also associated with 
a delay in the early, but not later, phase of tumour growth – an observation which 
phenocopies that seen for tumours grown in Ang-2 deficient mice, and is 
consistent with the known effects of Tie-2 activation. 
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Figure 14: Left, Tumour growth curve for orthotopic 4T1 mammary carcinoma. Treatment with 
AKB-9778 or control vehicle was begun 24h after cell implantation. Curves show a delay in the 
early phase of primary tumour growth (*p < 0.01 by 2 way ANOVA, n = 6 per group). Right, 
Tumour growth curves for orthotopic E0771 mammary carcinoma. Treatment with AKB-9778 or 
control vehicle was begun immediately after cell implantation (*p < 0.01 by 2 way ANOVA, n = 6 
per group). Note: in the first week of growth, AKB-9778 treated tumours grew as flat, ovoid 
discs whereas control tumours were spherical. 
 
Figure 15: Data from Figure 14 (left panel) is plotted again with a log(10) scale on the y axis. 
Curves demonstrate that the difference in primary tumour size is due exclusively to a delay in 
the early phase of tumour growth. 
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Figure 16: Representative fluorescent confocal micrographs of control 
treated (left panel) and AKB-9778 treated (right panel) tumours from the 
experiment depicted in Figure 17 (red, CD31; green, NG2; blue, DAPI).  
All error bars represent SD.  Arrows exemplify the difference in pericyte-
EC separation. 
  
Figure 17: 4T1 mammary carcinoma was implanted orthotopically and treatment 
with AKB-9778 or control vehicle was begun 24 h later. After 7-8 days (when growth 
rates of AKB-9778 and control-treated tumours are discrepant), tumours were 
harvested. Left: Pericyte coverage in control and AKB-9778 tumours is shown (NG2 
- pericyte marker; CD31 - endothelial cell marker; *p = 0.02 by 2-sided t-test, n = 5 
per group). Right: Distance between pericytes and endothelial cells in the same 
tumours shows increased distance between these cell types in control-treated 
tumours (*p = 0.05 by 2 sided t-test, n=5 per group). 
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5.2 The effects of AKB-9778 on the growth of metastatic tumours 
The earliest phase of primary tumour growth is not relevant to clinical oncology 
as patients only present once tumours are well established. At this time, 
however, there are often foci of disseminated tumour cells (micrometastases) 
that are clinically undetectable but may grow in subsequent years to form 
macrometastatic lesions. The rationale behind adjuvant therapy (systemic 
therapy given after resection of a primary tumour) is to prevent or delay the 
growth of these micrometastatic lesions. 
When circulating tumour cells lodge in the vessels of distant organs, they induce 
EC overexpression of Ang-2 and therefore facilitate vascular destabilization, 
followed by tumour cell extravasation into distant organ parenchyma (Holash et 
al., 1999, Holopainen et al., 2012, Avraham et al., 2014).   Given this, and the 
previous observation that VE-PTP inhibition with AKB-9778 delays the early 
phase of primary tumour growth, we next studied the effects of AKB-9778 on the 
early growth of metastatic lesions. 
5.2.1 Impact of adjuvant AKB-9778 therapy on the spontaneous metastatic 
burden 
A model of spontaneous 4T1 mammary carcinoma metastasis was used to 
specifically study the effects of VE-PTP inhibition on metastasis, (Figure 18).  
Through a series of pilot experiments performed in the Steele Laboratory, it was 
determined that micrometastatic clumps of tumour cells (less than 100 cells) 
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were typically first seen in the lungs of 4T1-tumour bearing mice once the 
primary tumour diameter reached 5mm (data not shown). 
Therefore, 4T1 tumours were implanted orthotopically and allowed to grow to 
5mm diameter before resection.  At this stage, mice were likely to have several 
micrometastatic lesions.  Mice were then randomly assigned to receive treatment 
with AKB-9778 or control vehicle, and sacrificed 3 weeks later. 
At sacrifice, full necropsy was performed with macroscopic examination of lungs, 
liver, lymph nodes, and bones.  AKB-9778 treated mice showed a reduction in 
the number of metastatic nodules in the lungs (Fig 19, left and Fig 20) and 
throughout the rest of the body including liver, lymph nodes, and bones (Fig 21).  
Furthermore, when the size of macroscopically detectable lung metastases was 
measured with stereomicroscopy, a shift towards smaller metastases in the lungs 
of AKB-9778 treated mice was seen (Fig 19, right). These results show that VE-
PTP inhibition delays the growth of spontaneously arising micrometastatic 
lesions into macroscopic metastases, reducing the overall metastatic burden. 
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Figure 18: Schema demonstrating model for adjuvant AKB-9778 therapy.  Tumours were 
resected at 5mm diameter. 
 
 
  
Figure 19: Left, Number of macroscopically detectable lung metastases in control vs. AKB-9778 
treated mice (*p = 0.033 by t-test, n = 10 per group) after 3 weeks’ treatment.  Right, Distribution 
of size of macrometastatic lung nodules (*p < 0.001 by chi-squared test).   
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Figure 20: Representative images of lungs visualized after resection in control (upper panels) and 
AKB-9778 treated (lower panels) mice (from the same experiment depicted in Figure 19). Scale 
bars = 10mm. 
 
Figure 21: Total number of macroscopically detected metastases (including lung, liver, bone, 
lymph node, and soft tissue) (*p = 0.029, n = 10 per group, from the same experiment depicted in 
Figure 19).   
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5.2.2 The effects of adjuvant AKB-9778 therapy upon the growth of 
spontaneous micrometastases 
To explore this finding in greater detail, the same experiment as described in 
Figure 18 was repeated, but lungs were resected after only 2 weeks of treatment.  
At this time point, macroscopic lung nodules were rarely seen.  Multiple histologic 
sections were taken through each lobe of each lung (as detailed in Materials and 
Methods) and with the assistance of a trained pathologist, histologically 
detectable metastatic lesions were identified, counted, and measured in cross-
sectional area using digital image analysis. 
The number of mice in which metastatic lesions were observed was not 
significantly different between AKB-9978 and control-treated mice (Fig 22, left).  
However, there was a significant reduction in the average cross-sectional area of 
metastatic lesions observed in AKB-9778- treated mice (Fig 22, right and Fig 23). 
These results are consistent with those from the immediately preceding 
experiment, and again show that VE-PTP inhibition slows the growth of 
micrometastatic lesions. 
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Figure 22: An adjuvant therapy model treating spontaneous metastasis was used as in Figure 18. 
Lungs were resected following 2 weeks of continuous treatment after primary tumour resection. 
Left, Number of mice with histologically detectable metastases (p = 0.38, two-sided Fisher’s exact 
test). Right, Mean area of micrometastases (*p = 0.05 by two-sided t-test, n = 10-11 mice per 
group, 3 sections through each lobe analyzed. Data show all metastases pooled).  
 
 
 
Figure 23: Representative histologic images of metastases in control (left panel, 40x original 
magnification) and AKB-9778 (right panel, 400x original magnification) treated lungs from the 
experiment depicted in Figure 22 (scale bars represent 500 µm in the left panel, 50 µm in the 
right panel).  
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5.2.3 Effect of adjuvant AKB-9778 on the extravasation of disseminated 
tumour cells into distant organ parenchyma 
We hypothesized that the effect of AKB-9778 upon metastasis growth was 
specifically due to improved vessel stabilization via activation of Tie-2 signaling.  
Models of experimental metastasis, in which mammary carcinoma cells are 
injected intravenously and AKB-9778 treatment commenced 24h later,  were 
used to test this hypothesis.   
4T1 tumour cells metastatic to the lung are known to have a prolonged 
intravascular growth phase before extravasation into surrounding parenchyma 
(Wong et al., 2002).  Here, 4T1 cells were injected intravenously and mice were 
treated for 8 days before resecting and analyzing lung tissue.  The lungs of AKB-
9778-treated mice showed significantly smaller micrometastases (Fig 24, left).  
Histologically, AKB-9778-treated mice showed clumps of micrometastatic cells 
lodged within alveolar vessels, while control vehicle-treated mice often showed 
cells that had extravasated into surrounding parenchyma (Fig 24, right).  This 
finding was confirmed upon staining serial sections of lung metastases with 
hematoxylin and eosin, and collagen IV (a vascular basement membrane 
marker).  AKB-9778 treated mice frequently showed tumour cells that had failed 
to breach the vascular basement membrane and enter the lung parenchyma (Fig 
25).  
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Figure 24: 4T1 tumour cells were injected intravenously and therapy with AKB-9778 or control 
commenced immediately. 9 days later lungs were resected and micrometastases identified 
histologically. Left, Data shows the number of tumour cells identified in hematoxylin and eosin 
stained sections of lung tissue. Each metastasis is represented by an individual data point. (*p 
< 0.01 by two-sided t-test, 6 mice per group, 3 sections of each lobe examined for each 
mouse).  Right, Representative H&E stained sections of micrometastases.  Control lungs 
(upper panels) show micrometastatic cells that have breached vascular boundaries and 
entered the alveolar airspace.  AKB-9778 treated lungs (lower panels) show cells tracking 
within vessels, yet to extravasate.  Scale bars = 100µm. 
 
 
 
Figure 25: Left, Number of intra- versus extra-vascular micrometastases (*p < 0.0001, n = 6 mice 
per group) from the same experiment depicted in Figure 24.   Right, Representative images of 
micrometastases.  Images show H&E stained sections of micrometastases and serial sections 
(separated by 5um) showing the same metastasis stained for collagen IV (brown).  Control mice 
show extravasation of tumour cells through the vascular basement membrane but AKB-9778 
treated mice show tumour cells retained within vessels.  Scale bar = 100µm. 
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Similar results were seen using an identical experimental system with E0771 
mammary carcinoma cells (in syngeneic mice, Fig 26), as well as primary tumour 
cells derived from tumours that had spontaneously arisen MMTV-PyVT 
transgenic animals (Fig 27).  
These results are consistent with those observed using the 4T1 model of 
spontaneous metastasis, and support the hypothesis that Tie-2 activation 
through VE-PTP inhibition increases vessel stability, preventing extravasation of 
metastatic tumour cells into the surrounding parenchymal tissue.  This in turn 
slows the growth of these metastatic lesions. 
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Figure 26: E0771 tumour cells were injected intravenously, therapy commenced, and 
lungs examined 5 days later. Graph shows ratio of intravascular to extravascular 
micrometastases (*p < 0.01 by Fisher’s exact test, all metastases for each treatment 
group pooled).  All error bars represent SD. 
  
Figure 27: Tumour cells isolated from MMTV:PyVT tumours were injected intravenously, therapy 
commenced, and lungs examined 5 days later. Left, Graph shows ratio of intravascular to 
extravascular micrometastases (*p < 0.01 by two-sided Fisher’s exact test, all metastases for 
each treatment group pooled).  Right, Representative images (40 x H&E staining) of experimental 
MMTV-PyVT tumour cell micrometastases treated with control (left panel) or AKB-9778 (right 
panel). Scale bars = 100µm. 
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5.2.4 The impact of adding of AKB-9778 to adjuvant chemotherapy upon 
mouse survival 
In clinical breast oncology, standard adjuvant therapy following surgery for high-
risk primary breast cancer includes cytotoxic chemotherapy.  Given the 
observation that VE-PTP inhibition delayed the growth of metastases in the 
adjuvant setting, we next tested whether the addition of AKB-9778 to standard 
chemotherapy would prove beneficial. 
Using the same experimental design as outlined in Figure 18, mice were 
randomized to post-operative therapy with doxorubicin chemotherapy, with or 
without the addition of AKB-9778.  Treatment was continued until animals met 
standard criteria for sacrifice.  In this experiment, the addition of AKB-9778 to 
adjuvant chemotherapy significantly improved mouse survival (Fig 28). 
Collectively, the data presented in section 5.2 show that pharmacological VE-
PTP inhibition hinders the growth of micrometastases.  This is due, at least in 
part, to the prevention of tumour cell extravasation, which likely relates to Tie-2 
hyperactivation reducing vessel permeability.  Finally, adjuvant VE-PTP inhibition 
improves mouse survival when added to standard chemotherapy. 
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Figure 28: Mouse survival after adjuvant therapy with doxorubicin +/- AKB-9778. (*p = 0.05 
using log-rank [Mantel-Cox] test, n = 8-9 mice per group) using a model of 4T1 
spontaneous metastasis.    
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5.3 The effects of AKB-9778 on the structure of established primary 
tumour vessels 
Having explored the consequences of VE-PTP inhibition on the early stages of 
both primary and metastatic tumour growth, the effects of AKB-9778 on more 
established primary tumours were studied next.  For the purposes of these 
studies, “established” tumours are defined as tumours that have reached a 
diameter of 3mm.  At this stage, they have passed through the “angiogenic 
switch” (Bergers and Benjamin, 2003), no longer rely solely upon the native host 
vasculature, and demonstrate robust angiogenesis with all the hallmarks of 
tumour vessels. 
The effect of AKB-9778 therapy on the structure of blood vessels was examined 
first.  We hypothesized that VE-PTP inhibition would enhance pericyte coverage, 
increase vessel diameter, and increase vessel density – all consistent with the 
effects of Tie-2 activation (Suri et al., 1998, Thurston et al., 1999) 
5.3.1 Impact of AKB-9778 treatment of established primary tumours upon 
pericyte coverage of endothelial cells 
4T1 mammary carcinoma cells were implanted into female mice and observed 
until tumours reached a diameter of 3mm.  At this point, a 10-day treatment 
course with either AKB-9778 or control vehicle was initiated.  Double 
immunofluorescent staining of resected tumours for pericyte (NG2 or desmin), 
and EC (CD31) markers was performed, and entire tumour cross sections were 
imaged by confocal microscopy and digitally analyzed.  AKB-9778 therapy led to 
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more structurally mature vessels, evidenced by increased perivascular cell 
coverage (defined as the percentage of total CD31+ area showing co-localization 
for pericyte staining, Figures 29, 30).  In addition, the mean distance between 
pericytes and ECs was significantly shorter in AKB-9778 treated tumours.  
Similar results were seen for E0771 mammary tumours, using an identical 
experimental design (Fig 31). 
Sections from the 4T1 tumours in this experiment were also double-stained for 
the EC junctional protein VE-Cadherin, and CD31. Consistent with our in vitro 
data, total VE-Cadherin levels in tumour ECs were unchanged after nine days of 
AKB-9778 therapy (Fig 32). 
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Figure 30: Enhanced vascular pericyte coverage in AKB-9778 treated 4T1 tumours (right panel) 
compared to control-treated tumours (left panel) (red = CD31, green = NG2, blue = DAPI).  White 
arrows indicate pericytes in control treated tumours that are distant from endothelial cells. 
 
  
 
Figure 29: Left, Colocalization of CD31+ area (endothelial cells) and NG2+ area (perivascular 
cells) (*p=0.049 by t-test, n = 6 per group) in 4T1 tumours. Centre, Colocalization of CD31+ area 
(endothelial cells) and desmin+ area (perivascular cells) (*p = 0.014 by t-test, n = 6 per group) in 
4T1 tumours. Right, Mean distance between desmin+ pericytes and CD31+ endothelial cells (*p = 
0.004 by t-test, n = 6 per group) in 4T1 tumours. 
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Figure 31: Colocalization of CD31+ area (endothelial cells) and NG2+ area 
(perivascular cells) (*p = 0.049 by t-test, n = 6 per group) in E0771 tumours (*p = 
0.006, n=6 per group). 
 
Figure 32: Orthotopic primary 4T1 breast tumours were treated with AKB-
9778 or control once reaching diameter 3mm for 10 days. Graph depicts 
colocalization of VE-Cadherin and CD31 staining (p = 0.82 by two-sided t-
test, n = 6 per group). 
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5.3.2 Impact of AKB-9778 treatment of established primary tumours upon 
vascular diameter 
Whole tumour cross-sectional confocal micrographs from the experiments 
described in 5.3.1 were then analyzed to determine the mean vessel diameter in 
4T1 and E0771 tumours.  Using this algorithm, between 3000 and 10,000 vessel 
segments were analyzed for each individual tumour.  In both models, there was a 
significant increase in vascular diameter in AKB-9778 treated tumours (Fig 33), 
by approximately 10 percent. 
5.3.3 Impact of AKB-9778 treatment of established primary tumours upon 
vessel density 
Finally, the mean microvessel density within tumours from the experiments 
described in 5.3.1 was determined. Detailed methodology is provided in the 
Materials and Methods chapter, but in brief a previously developed segmentation 
algorithm was used to delineate the entire vasculature into individual vessel 
segments.  Vessel density was defined as the number of vessel segments per 
unit area. There was a statistically significant increase in tumour vessel density in 
both 4T1 and E0771 tumours treated with AKB-9778 (Fig 34). 
Collectively, the results presented in section 5.3 show that pharmacologic VE-
PTP inhibition within established primary mammary carcinomas enhances the 
structural maturity of vessels, and increases vascular diameter and density.  
These findings are consistent with the phenotype expected as a result of Tie-2 
hyperactivation. 
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Figure 34: Vessel density in control versus AKB-9778 treated 4T1 (left) and E0771 (right) tumours 
(4T1: *p = 0.05 by t-test, n = 6 per group; E0771: *p = 0.05, n = 6 per group). 
 
 
 
 
Figure 33: Vessel diameter in control versus AKB-9778 treated 4T1 (left) and E0771 (right) 
tumours (4T1: *p=0.0032 by t-test, n=6 per group; E0771: *p = 0.001, n = 6 per group).   
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5.4 The effects of AKB-9778 on the function of established primary 
tumour vessels 
Attention was next turned to changes in the function of established primary 
tumour vessels after treatment with AKB-9778.  Given previous findings of 
enhanced pericyte coverage, increased vessel diameter, and increased vessel 
density after AKB-9778 treatment, and the known effects of enhanced Tie-2 
activity (Suri et al., 1998, Thurston et al., 1999), we hypothesized that VE-PTP 
inhibition would result in reduced tumour vessel permeability, enhanced tumour 
perfusion by blood, and a reduction in tumour hypoxia. 
5.4.1 Effect of AKB-9778 treatment of established primary tumours upon 
vascular permeability 
To assess changes in tumour vessel permeability after VE-PTP inhibition, 
intravital microscopy of 4T1 tumours was performed, and the extravasation of 
intravenously injected bovine serum albumin was quantified at two time points – 
before initiation of therapy (tumour diameter 3-4mm) and again after 72h of 
therapy.  As would be expected in a rapidly growing tumour with robust 
angiogenesis, control tumours showed an increase in tumour vessel permeability 
over time.  This was entirely mitigated by AKB-9778 treatment (Fig 35). 
5.4.2 Impact of AKB-9778 treatment of established primary tumours upon 
vascular perfusion 
Changes in tumour blood perfusion after AKB-9778 treatment were next assayed 
in both the 4T1 and E0771 models.  Treatment was begun once tumours 
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reached 3mm in size, and continued for 10 days.  At this point, biotinylated lectin 
(a marker of perfused vessels) was injected intravenously and tumours were 
harvested 5 minutes later.  Stained sections of tumour tissue were stained for 
CD31 and lectin, and the [lectin+ area/total tumour area] and 
[lectin+CD31+area/total tumour area] fractions were quantified.  In both models, 
there was a significant increase in tumour perfusion with AKB-9778 treatment 
(Figs 36-38). 
To further visualize changes in tumour perfusion after AKB-9778 therapy, we 
grew orthotopic 4T1 tumours under mammary fat pad windows and performed 
optical frequency domain imaging (OFDI) of the tumour vasculature before and 
after 4 days of AKB-9778 treatment.  This imaging modality provides a detailed 
landscape of only vessels that are perfused, and that have a diameter 8-9µM or 
greater, to a depth of 800µM.  Qualitative assessment showed a marked 
increase in tumour perfusion after 4 days of AKB-9778 therapy (Fig 39). 
 
  
  105 
 
 
 
Figure 35: Left, Percentage change in permeability from baseline to after 72 h of treatment in 
control vs AKB-9778 treated 4T1 tumours (*p = 0.029 by t-test, n=3 per group). Right, Intravital 
micrographs taken 0 minutes and 1 hr after intravenous injection of fluorescent bovine serum 
albumin after treatment with control (top panels) or AKB-9778 (lower panels).  Scale bar = 
200uM. 
 
Figure 36: Established 4T1 orthotopic tumours were treated with AKB-9778 or control for 10 days 
and harvested 5 minutes after intravenous injection of lectin. Left, Lectin positive area in control 
versus AKB-9778 treated tumours (*p=0.029 by t-test, n=6 per group.  Right, Graph depicts 
lectin-CD31 double positive area as a proportion of total tumour area (p = 0.12 by two-sided t-
test, n = 6 per group).   
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Figure 37: Lectin positive area in control versus AKB-9778 treated E0771 
tumours (*p = 0.049, n = 5 per group).  
 
 
Figure 38: Enhanced vessel perfusion by lectin in AKB-9778 treated tumours compared to control 
(green = lectin, red = CD31, blue = DAPI). 
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Figure 39: Intravital optical frequency domain imaging (OFDI) of 4T1 mammary carcinomas at 
baseline (Day 0, diameter 2-3mm) and after 4 days’ treatment with AKB-9778 or control vehicle.  
Images show perfused vessels only.   Scale bar represents 3mm. 
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5.4.3 Impact of AKB-9778 treatment of established primary tumours upon 
tumour hypoxia 
We anticipated that improved perfusion within solid tumours after VE-PTP 
inhibition would lead to a reduction in tumour hypoxia.  To test this hypothesis, 
experiments with an identical design to those described in 5.4.2 were performed.  
Instead of injecting lectin, mice were injected with pimonidazole 1h before 
sacrifice, and tumours were stained for redox markers as a measure of 
intratumoural hypoxia.  In both models, there was a decrease in the hypoxic 
fraction in AKB-9778-treated tumours (Fig 40). 
5.4.4 AKB-9778 treatment of established primary tumours does not alter 
their growth rate 
Having observed several changes in vascular structure and function upon VE-
PTP inhibition in established mammary tumours, we next asked if these were 
associated with any change in tumour growth rate.  Data from 4 different tumour 
models, including the spontaneously arising MMTV:PyVT transgenic mouse 
model, showed that initiation of AKB-9778 treatment at a time when tumours 
measured 3mm in diameter had no impact upon the tumour growth rate (Fig 41). 
5.4.5 AKB-9778 pre-treatment of established primary tumours potentiates 
the effect of external beam radiotherapy 
Given the observed reduction in hypoxia (a known impediment to 
radiosensitivity), the effect of AKB-9778 pre-treatment on the efficacy of tumour 
radiotherapy was studied next. 4T1 mammary tumours were implanted  
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Figure 40: Relative hypoxic fraction assessed by pimonidazole staining in control vs AKB-9778 
treated 4T1 (left) and E0771 (right) tumours (4T1: *p = 0.05, n = 10-13 per group; E0771: *p = 
0.038, n = 9-10 per group).  
 
Figure 41: Effect of VE-PTP inhibition on the growth of established orthotopic primary tumours.  
For each experiment, treatment was commenced a tumour diameter 3mm. n = 6-8 mice per 
group).  All error bars represent SD. 
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orthotopically, and at diameter 3mm were treated for 1 week with either AKB-
9778 or control vehicle.  Half of the mice from each treatment arm were then 
administered a single fraction of external beam radiation (20Gy) focused on the 
mammary tumour.  As expected, AKB-9778 treatment alone had no impact upon 
tumour growth. However, pre-treatment with AKB-9778 significantly enhanced 
the efficacy of subsequently delivered radiation (Fig 42). 
 
Collectively, the data presented in section 5.4 show that pharmacologic inhibition 
of VE-PTP reduces tumour vessel permeability, enhances perfusion, and 
reduces tumour hypoxia – effects which are all consistent with increased Tie-2 
activity. These changes are not associated with an alteration of primary tumour 
growth per se, but do enhance the efficacy of radiotherapy, the efficacy of which 
is dependent on adequate tissue oxygenation. 
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Figure 42: 4T1 tumour growth curves from combined AKB-9778 and radiotherapy.  Treatment 
was begun at diameter 3mm, and radiotherapy given 1 week later.  (*p < 0.001 comparing green 
and pink lines by ANOVA, n = 7 per group).   
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6 The effects of AKB-9778 on vessels within normal 
tissue 
As a VE-PTP inhibitor, AKB-9778 is being moved into clinical trials for a variety of 
human diseases.  Therefore in addition to assessing the efficacy of the 
compound in various tumour models, experiments were performed to assess the 
effects of AKB-9778 on normal host vessels, with the goal of obtaining 
preliminary insights into potential toxicities of the drug. 
6.1 Impact of AKB-9778 on cutaneous vasculature permeability 
Normal tissue vasculature has a basal level of permeability, which is essential for 
the maintenance of microenvironmental homeostasis (Nagy et al., 2008).   To 
determine the effect of AKB-9778 on normal vessel permeability, non-tumour 
bearing adult mice were treated with AKB-9778 or control for 24h. A Miles assay 
was then performed – this is a well-established tool for measuring vascular 
permeability to molecules the size of albumin.  In keeping with its capacity to 
activate Tie-2, AKB-9778 caused a reduction in cutaneous vascular permeability 
(Fig 43).  
6.2 Impact of AKB-9778 on cutaneous vessel diameter and systemic 
blood pressure 
The impact of AKB-9778 on cutaneous vessel diameter was assessed next. 
Healthy adult mice were treated for 48h and the mean vessel diameter (vessels 
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stained for CD31) in fragments of flank skin was quantified.  There was a 
significant increase in mean cutaneous vessel diameter seen in treated animals 
(Fig 44, left).  We expected that this might lead to a reduction in systemic 
vascular resistance and hence systemic blood pressure.  Notably, 72h of AKB-
9778 therapy did not significantly lower mean arterial pressure in healthy adult 
mice (Fig 44, right). 
Collectively, the data presented in Chapter Six show that pharmacologic 
inhibition of VE-PTP invokes similar changes in the vessels of normal tissue (ie. 
increased diameter and reduced permeability) as those we previously observed 
in tumours.  The phenotype is consistent with that observed with Tie-2 activation 
(Suri et al., 1998, Thurston et al., 1999). 
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Figure 43: Miles assay demonstrating Evans Blue extravasation in skin of healthy 
mice pre-treated with control vehicle or AKB-9778 for 24h (*p < 0.01 by two-sided 
t-test, n = 4 per group). 
 
 
Figure 44: Left, Cutaneous vessel diameter in non-tumour bearing mice after 48h of treatment 
with control or AKB-9778 (*p = 0.04 by two-sided t-test, n = 3 per group).  Right, Mean Arterial 
Pressure in tumour-bearing mice treated for 72h with AKB-9778 or control vehicle (p = 0.38 by 
two-sided t-test, n = 5 per group).   
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7 The role of endothelial nitric oxide synthase in 
mediating the effects of AKB-9778 on primary tumour 
vessels 
In a non-tumour setting, Tie-2 mediated angiogenesis has been found to be 
dependent on the activity of endothelial nitric oxide synthase (eNOS) (Babaei et 
al., 2003).  We had previously observed that by enhancing Tie-2 signaling, AKB-
9778 induces activation of the endothelial nitric oxide synthase (eNOS), via 
phosphorylation at its ser1177 residue (Fig 4).  Given this finding, we next 
explored whether VE-PTP inhibition increases EC production of nitric oxide (NO), 
and if so, whether eNOS-derived NO mediates the increases in tumour vessel 
density and diameter seen after VE-PTP inhibition with AKB-9778.  
7.1 Impact of AKB-9778 on endothelial nitric oxide synthase activation 
and endothelial cell production of nitric oxide 
In addition to its stimulatory ser1177 residue, eNOS activity can be inhibited by 
phosphorylation at its Thr495 residue. To further characterize the effects of AKB-
9778 on eNOS in ECs, HUVECs were treated with AKB-9778 or Ang-1 (both Tie-
2 activating stimuli).  Neither enhanced phosphorylation at Thr495 (Fig 45).  This 
suggests that VE-PTP inhibition alters eNOS phosphorylation patterns in a 
manner that increases its activity. 
EC production of NO in response to AKB-9778 was assayed next using 4,5-
diaminofluorescein diacetate (DAF-2 DA), an established marker of NO 
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production. AKB-9778 induced a marked increase in EC NO production (Fig 46).  
This effect could be suppressed with the use of the NOS inhibitor NG-
Monomethyl-L-arginine, showing that the increase in NO production is NOS-
mediated.  
7.2 The role of endothelial nitric oxide synthase as a mediator of AKB-
9778-induced changes in tumour vessel diameter and density  
Given our finding that AKB-9778 activates EC eNOS in a Tie-2 dependent 
manner, and that this in turn increases EC production of NO, we next asked 
whether the changes in tumour vessel phenotype observed after AKB-9778 
treatment (increased vessel density and diameter) were mediated by eNOS 
activation.   E0771 mammary carcinoma cells were implanted orthotopically into 
wild-type C57Bl6/J and eNOS-/- mice bred on a C57Bl6/J background. 
When tumours reached 3mm in size, treatment was begun with either AKB-9778 
or control vehicle.  Firstly, when administered to eNOS-deficient mice, AKB-9778 
therapy had no effect on tumour growth (Fig 47).  Most notably, however, AKB-
9778 therapy did not significantly increase vessel density or vessel diameter in 
eNOS-/- mice (Fig 48).  These data stand in contrast to those seen in wild-type 
mice (Fig 33-34), and suggest that the changes in vessel density and diameter 
seen after AKB-9778 treatment are eNOS-dependent, at least in part. 
Collectively, the data presented in Chapter Seven show that VE-PTP inhibition by 
AKB-9778 leads to activation of eNOS, which increases EC production of NO 
and in turn increases the number and size of tumour vessels. 
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Figure 45: Top, eNOS phosphorylation (Thr495) and total eNOS in HUVEC lysates 
after AKB-9778 treatment. Bottom eNOS phosphorylation (Thr495) and total eNOS 
in HUVEC lysates after Angiopoietin-1 and/or AKB-9778 treatment for 30 minutes. 
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Figure 46: Top, HUVEC nitric oxide production in vitro after treatment with control, AKB-
9778, or L-NMMA.  Nitric oxide production was determined by quantification of the 
fluorescent signal from DAF-2T.  Bottom, Representative images of DAF-2T fluorescence 
in HUVECs after treatment with control (left panel), AKB-9778 (center panel), or AKB-9778 
and L-NMMA (right panel).  Scale bar = 20µm. 
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Figure 47: E0771 mammary carcinoma was implanted orthotopically into either wild-type (WT) 
C57Bl/6 mice or eNOS-/- mice (KO). At tumour diameter of 3mm, mice were treated with either 
AKB-9778 or control vehicle (n = 5 per group). Data show tumour growth curves. 
 
Figure 48: Left, Vessel diameter in E0771 orthotopic mammary carcinomas treated with AKB-
9778 or control vehicle in eNOS-/- mice (p = 0.40, n = 5 per group).  Right, Vessel density in 
E0771 orthotopic mammary carcinomas treated with AKB-9778 or control vehicle in eNOS-/- mice 
(p = 0.77, n = 5 per group).   
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8 Discussion 
8.1 Introduction 
The data presented within this dissertation and its publication in the peer-
reviewed literature (Goel et al., 2013) are, to the best of our knowledge, the first 
to describe the effects of VE-PTP inhibition as a therapeutic strategy in any 
disease.   We report that the novel, first-in-class VE-PTP inhibitor AKB-9778 is a 
potent activator of Tie-2 signaling within the endothelium, both in vitro and in 
vivo. AKB-9778 is the first small molecule inhibitor to activate Tie-2, and in doing 
so provides immense potential as a therapeutic agent in a number of disease 
settings where enhanced Tie-2 activity has conceivable beneficial effects.  
Through a series of in vitro experiments, we show that AKB-9778 not only 
increases Tie-2 tyrosine phosphorylation, but also activates canonical signaling 
pathways downstream of Tie-2 (Augustin et al., 2009).  Importantly, this occurs 
independently of the actions of Ang-1 and Ang-2.  We then show in a number of 
mouse models of breast cancer that AKB-9778 therapy creates a more stable, 
mature vasculature characterized by a greater number of vessels which are also 
larger and relatively non-permeable.  Although not conclusively proven in this 
study, this phenotype is likely a consequence Tie-2 activation.   
In this chapter, we discuss the results of our experiments in detail, 
contextualizing them amongst other reports in the literature. We also discuss the 
limitations of this work, and suggest directions for future investigations into VE-
PTP inhibition. 
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8.2 Vascular stability – a unifying theme  
Within solid tumours, a large number of pro-angiogenic factors conspire to 
promote the formation of new blood vessels (Goel et al., 2011, Jain, 2001, Jain, 
2005, Dvorak, 1986, Folkman, 1971, Kim et al., 1993, Holash et al., 1999, Yuan 
et al., 1996, Senger et al., 1983).  Unlike in instances of physiologic angiogenesis 
(e.g. wound healing, ovulation), blood vessel growth in tumours occurs in a 
relentless, dysregulated fashion (Dvorak, 1986), primarily because the release of 
pro-angiogenic factors from tumour and stromal cells is not under tight control 
(Mazzone et al., 2009, Semenza, 2010b, Raza et al., 2010, Fukumura et al., 
1998). 
As a consequence of this excess in pro-angiogenic factors, vessels within solid 
tumours display a series of characteristic structural and functional abnormalities 
(Goel et al., 2011, Abramsson et al., 2003, Inai et al., 2004, Morikawa et al., 
2002, Tong et al., 2004, Kamoun et al., 2009, Winkler et al., 2004).  These 
abnormalities are well summarized by the terms “vascular immaturity” and 
“vascular instability”.  Immature, unstable vessels are characterized by reduced 
perivascular cell coverage (Weis et al., 2004, Greenberg et al., 2008, Abramsson 
et al., 2003, Inai et al., 2004, Morikawa et al., 2002), a patchy basement 
membrane (Winkler et al., 2004, Kamoun et al., 2009), and hyperpermeability 
(Weis et al., 2004, Dvorak, 1990, Jain, 2003, Stohrer et al., 2000).   
In the early phases of tumour development, vascular destabilization and loss of 
pericyte coverage facilitate the onset of sprouting angiogenesis, and hence 
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tumour growth (Holash et al., 1999, Nasarre et al., 2009).  Within more 
established tumours, hyperpermeability increases interstitial fluid pressure, and 
chaotic blood flow promotes hypoxia – both of which exacerbate malignant traits 
and hinder the effectiveness of anti-cancer therapies (Goel et al., 2011, Tong et 
al., 2004, Winkler et al., 2004, Pennacchietti et al., 2003, Boucher et al., 1990, 
Boucher et al., 1991).  Finally, the development of metastases relies upon local 
hyperpermeability in distant organ vessels, facilitating tumour cell extravasation 
(Holash et al., 1999, Holopainen et al., 2012, Wong et al., 2002, Weis et al., 
2004, Avraham et al., 2014).  For all of these reasons, strategies to reverse 
instability and immaturity in tumour vessels are theoretically very attractive.  
The most concerted efforts to achieve this goal have relied upon pharmacologic 
blockade of the VEGF-A pathway.  Such agents include the monoclonal antibody 
bevacizumab, a plethora of VEGF tyrosine kinase inhibitors, and the VEGF-trap 
aflibercept  (Jain and Carmeliet, 2012).  By inhibiting VEGF-driven abnormalities 
within vessels, such agents can transiently reverse some of their structural and 
functional abnormalities, a process coined “vascular normalization” (Jain, 2005, 
Goel et al., 2011).  Unfortunately, pre-clinical studies suggest that this 
normalization is only a transient phenomenon, as prolonged inhibition of the 
VEGF pathway can eventually lead to vascular pruning and increased tumour 
hypoxia. 
Manipulation of Tie-2 activity is a very attractive strategy to modulate vascular 
stability.  Although the effects of individual ligands upon Tie-2 signaling are 
complex, it is clear that Tie-2 activation invokes a more mature, stable vascular 
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phenotype (Suri et al., 1998, Thurston et al., 1999, Gamble et al., 2000) and 
should not promote pruning of vessels.  Theoretically, therefore, increasing Tie-2 
activity within tumours could alleviate some of the negative consequences of 
vascular destabilization described above. 
Given that VE-PTP can negatively regulate Tie-2 (Winderlich et al., 2009), we 
speculated that inhibition of VE-PTP activity might enhance vascular stability in 
tumours through enhancement of Tie-2 activity.  Fortuitously, AKB-9778 was 
being introduced into preclinical studies at this time, and we therefore embarked 
upon the current study. 
In each of the three phases of tumour progression (early primary tumour 
development, growth of established primary tumours, progression of metastatic 
lesions), we have shown that VE-PTP inhibition results in a more stable vascular 
phenotype (Goel et al., 2013, Kontos and Willett, 2013).  This common theme 
unifies the results of our studies within solid tumours.  In early primary tumour 
growth, the enforcement of perivascular cell coverage in host vessels was found 
to delay the early phases of tumour growth.  In more established tumours, 
maintenance of vessel integrity improved perfusion, reduced hypoxia, and 
enhanced the efficacy of radiotherapy.  Finally in developing metastatic lesions, 
inhibition of VE-PTP reduced circulating tumour cell extravasation into distant 
organs – in turn delaying the growth of metastases and prolonging mouse 
survival.  The finding of our study and their relationship to vascular phenotype 
are summarized in Fig 49.   
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Fig 49: Inhibition of the VE-PTP phosphatase domain in endothelial cells activates Tie-2 signaling, in turn 
promoting a more stable vessel phenotype. In early tumour growth, this prevents early destabilization and hence 
slows the initial phase of tumour progression.  In established tumours, vessels show structural and functional 
changes of normalization, resulting in improved tumour perfusion (which occurs due to an increased production 
of nitric oxide by endothelial eNOS).  In the setting of micrometastasis, stabilization of distant organ vessels 
prevents extravasation of tumour cells, delaying micrometastatic progression and prolonging survival.   
Note: some of the molecular pathways highlighted in this figure (ie. survivin and caspase-3 downstream of Tie-2) 
are extrapolated from the literature and not addressed in the current study. 
Figure taken from Goel et al, 2013. 
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8.3 The mechanism of action for AKB-9778 
AKB-9778 has been developed as a potent and selective inhibitor of VE-PTP 
through structural modifications of 1,2,3,4-tetrahydroisoquinolinyl sulfamic acids. 
These acids are phosphotyrosine mimetics, and act competitively to prevent 
phosphatases from dephosphorylating their endogenous targets.  Coupling 
1,2,3,4-tetrahydroisoquinolinyl sulfamic acids to a malonate template yields 
selective and potent inhibitors of VE-PTP (Amarasinghe et al., 2006).  As 
detailed in the Introduction, AKB-9778 shows great potency and selectivity for 
VE-PTP. 
Of interest, we found that AKB-9778 induced Tie-2 activation in a ligand-
independent fashion.  Endothelial cells grown in standard media, or in the 
presence of Ang-1 and/or Ang-2, all showed strong increases in p-AKT and p-
eNOS after exposure to AKB-9778 in vitro.  That is to say, we observed 
compound-induced Tie-2 activation in a ligand-independent fashion.  Importantly, 
a second, independent report has been published since the completion of this 
work (Shen et al, 2014), which also reports identical findings after exposing 
endothelial cells in vitro to AKB-9778.  
This finding is consistent with the notion that VE-PTP serves as a constant 
regulator of Tie-2, balancing Tie-2 activity within endothelial cells.  Elegant 
studies from the laboratory of Vestweber have demonstrated that upon Tie-2 
phosphorylation through Ang-1, VE-PTP serves to rapidly dephosphorylate Tie-2, 
serving as a constant negative feedback regulator of Tie-2 activation (Winderlich 
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et al., 2009).  Given that there is always some basal level of Tie-2 
phosphorylation within endothelial cells, it is certainly plausible that the continued 
presence of a VE-PTP inhibitor would allow for the accumulation of 
phosphorylated Tie-2 over time, regardless of the ligand context. 
We also observed indirect evidence for the ligand-independent activity of AKB-
9778 in vivo.  As shown in Figure 7, AKB-9778 phosphorylated Tie-2 in both 
normal lung tissue (with low levels of Ang-2) and mammary tumour tissue (where 
Ang-2 levels are typically higher (Koh et al., 2010)).  
This is an important point when drawing comparisons between VE-PTP inhibition 
and another pharmacologic strategy targeting the same pathway, namely Ang-2 
inhibition. Firstly, inter- and intra-tumour levels of Ang-2 are highly variable 
(Sfiligoi et al., 2003) and anti-Ang-2 strategies can only be effective in tumours 
and regions that express sufficient levels of Ang-2. In contrast, we show that VE-
PTP inhibition activates Tie-2 regardless of ligand context. Secondly, since 
tumours typically express higher levels of Ang-2 than Ang-1 (Koh et al., 2010), 
sequestering Ang-2 with monoclonal antibodies may not necessarily lead to Tie-2 
activation in tumour ECs, as there is little Tie-2 agonist in the microenvironment. 
In contrast, VE-PTP inhibition consistently activates Tie-2, even in the presence 
of Ang-2, and its downstream effector pathways.   
As such, one could speculate that Ang-2 blockade might induce a greater level of 
vascular regression (given that VEGF and Ang-2 act in concert to fuel 
angiogenesis), whereas VE-PTP inhibition might encourage vascular stabilization 
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without regression (as Tie-2 activation encourages the formation of mature, 
stable vessels).  Unfortunately, we were unable to test these approaches directly 
given policies of pharmaceutical companies prohibiting head-to-head 
comparisons of investigational agents manufactured by different entities.  Indeed, 
these concepts are consistent with observations in the published literature (Leow 
et al., 2012, Koh et al., 2010) and our own studies (Goel et al., 2013). VE-PTP 
inhibition therefore provides a unique opportunity to “hyperactivate” Tie-2 within 
solid tumours. 
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8.4 Other potential effects of VE-PTP inhibition  
Of all the potential VE-PTP substrates, its interaction with Tie-2 in ECs is 
perhaps the best characterized and as is discussed in Chapter One, VE-PTP 
serves an important role as a negative feedback regulator of Tie-2 activity in 
normal cellular homeostasis (Winderlich et al., 2009). As such, we focused our 
initial in vitro studies upon the impact of AKB-9778 on Tie-2 activity within the 
endothelium. 
However, the published literature regarding the function of VE-PTP in endothelial 
cells is more complex than this, and other potential binding partners have been 
identified (Kuppers et al., 2014).  Indeed, although detailed exploration of other 
VE-PTP related pathways is outside the scope of this study, our relatively 
singular focus on Tie-2 activity is a limitation of this work.   
Unlike the case for Tie-2, the precise interactions between VE-PTP and other 
potential substrates have not been clearly defined and it is therefore difficult to 
accurately predict how VE-PTP catalytic domain inhibition might affect these 
interactions and change the vascular phenotype.  As is described in previous 
chapters, other potential interactors (either directly or indirectly) include the 
endothelial junctional proteins VE-Cadherin (Nawroth et al., 2002) and 
plakoglobin (Nottebaum et al., 2008), and possibly VEGFR2 (Hayashi et al., 
2013).   
The interaction between VE-PTP and VE-Cadherin is complex.  It has been 
shown that these two molecules associate via their membrane-proximal 
  129 
extracellular domains (Nawroth et al., 2002).  In our studies, we found that 
inhibition of VE-PTP activity lead to reduced vessel permeability in vivo, 
consistent with increased Tie-2 activity.  In contrast, in vitro studies by others 
have suggested that internalization and degradation of VE-PTP leads to 
increased tyrosine phosphorylation of VE-Cadherin and an associated decrease 
in endothelial barrier integrity (Nawroth et al., 2002).  Although it may seem 
difficult to reconcile these findings, the latter study did report that this 
phenomenon was specifically dependent upon the extracellular binding between 
VE-PTP and VE-Cadherin, and not the VE-PTP catalytic domain.  It is therefore 
conceivable that as a pure phosphatase inhibitor, AKB-9778 promotes Tie-2 
activation (and hence reduced permeability) without disrupting VE-Cadherin/VE-
PTP binding.   
In keeping with this, we found that although AKB-9778 increased tyrosine 
phosphorylation of VE-Cadherin, there was no change in the total amount of VE-
Cadherin at the cell membrane of endothelial cells treated with this compound. 
Beyond VE-Cadherin, another report has implicated an interaction between VE-
PTP and the endothelial junctional complex protein plakoglobin (otherwise known 
as gamma catenin) (Nottebaum et al., 2008).  In this study, downregulation of 
VE-PTP caused tyrosine phosphorylation of plakoglobin and VE-Cadherin.  This 
was again associated with a reduction in EC junctional integrity.  However, the 
distinct roles of VE-PTP’s extracellular and phosphatase domains in this process 
were not defined. 
  130 
Importantly, we observed strong reductions in tumour vessel permeability with 
AKB-9778 treatment, consistent with Tie-2 activation and not with impaired EC 
junctional integrity. Collectively, these data suggest that the effects of 
pharmacological VE-PTP phosphatase domain inhibition are mediated primarily 
through increased Tie-2 kinase activity. 
More recently, Hayashi et al reported a possible interaction between VE-PTP and 
VEGFR2.  The investigators suggested that suppression of VE-PTP activity 
might indirectly increase VEGFR2 phosphorylation (and thus conceivably 
increase permeability and promote vascular immaturity) (Hayashi et al., 2013).  
At present, this remains an isolated report, and stands in contrast to data from 
the original study in which VE-PTP was first discovered (Fachinger et al., 1999).  
We did not study the status of VEGFR2 phosphorylation after AKB-9778 
treatment in our studies, and this is an issue that warrants further clarification. 
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8.5 VE-PTP in embryonic angiogenesis 
Like many key regulators of angiogenesis, VE-PTP is critical to successful 
embryogenesis and two different VE-PTP null mice both show an embryonic 
lethal phenotype (Baumer et al., 2006, Dominguez et al., 2007).  The defects 
seen in these mice include dramatic enlargement of yolk sac vessels and a 
complete failure to elaborate the primitive vascular scaffold into higher-order 
branched arteries, veins, and capillaries.  These changes have generally been 
attributed to Tie-2 hyperactivation (Dominguez et al., 2007).   
We have utilized a different model of embryonic angiogenesis to assess the 
effects of pharmacologic VE-PTP inhibition, namely the zebrafish angiogenesis 
assay.  It should be pointed out that there are several limitations with this 
approach.  Firstly, due to the poor permeability of AKB-9778 into the zebrafish 
embryo, high concentrations are required within the fish water.  It is therefore 
possible that some of the observed phenotype relates to non-specific or “off-
target” effects.  Secondly, the angiopoietin/Tie system in zebrafish is markedly 
distinct to that in mice or humans (Gjini et al., 2011), and it is not clear to what 
extent our findings are therefore applicable to mammalian systems. 
It is worth noting that the discrepancy between the effects of AKB-9778 on 
embryonic angiogenesis (reduced sprouting and vessel density) and adult 
tumour vessels (increased vessel density) are not unexpected, and are in 
keeping with the distinct roles of several angiogenic factors in embryonic versus 
adult organisms (Maisonpierre et al., 1997, Suri et al., 1996, Dumont et al., 1994, 
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Carmeliet et al., 1996, Sato et al., 1995).  Our zebrafish xenograft model, 
although looking at tumour angiogenesis, takes place in the context of 
embryogenesis, and as such the findings of reduced vessel density after AKB-
9778 treatment in this experiment (Fig 13), cannot necessarily be compared with 
those seen in mouse tumours.   
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8.6 The role of VE-PTP in the early phase of tumour growth 
In section 5.1, we show that AKB-9778 therapy delays the early phase of primary 
mammary tumour growth.  Early in primary tumour development, cancer cells co-
opt host vessels that then upregulate production of Ang-2 (Holash et al., 1999) 
and VE-PTP (Dominguez et al., 2007), presumably leading to Tie-2 deactivation, 
vessel destabilization, and sprouting angiogenesis (Holash et al., 1999).  
We had hypothesized that VE-PTP inhibition during early tumour development 
would stabilize host vessels, delaying the onset of angiogenesis, and indeed 
found that the onset of vascular destabilization was delayed with AKB-9778 
therapy. Collectively, these data show that VE-PTP inhibition delays the initial 
phase of tumour growth by upholding vascular maturity in host vessels. 
These data are consistent with the results seen when growing tumours in Ang2-/- 
mice (Nasarre et al., 2009).  However, one difference between our results and 
those published in Ang2-/- mice is that the latter study also observed a reduction 
in the diameters of intratumoural microvessels during this early growth phase.  
This discrepancy speaks further to the differences between Ang-2 blockade and 
VE-PTP inhibition, as discussed earlier. 
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8.7 The role of VE-PTP in the development and progression of 
metastases 
Perhaps the most striking results of the present study are the findings that VE-
PTP inhibition prevents the extravasation of circulating tumour cells into the 
parenchyma of distant organs, thus leading to a slowing in the growth of 
metastatic lesions and a prolonging of mouse survival. Indeed, clinical studies of 
vessel-targeted therapies in the “adjuvant” setting have been uniformly negative 
(Allegra et al., 2011, Cameron et al., 2013), and to our knowledge this is the first 
study – clinical or preclinical - to show a benefit from targeting the vasculature 
immediately after resection of a primary tumour.  
The extravasation of tumour cells into distant organs is an important component 
of the metastatic cascade (Talmadge and Fidler, 2010).  Critically, it requires an 
interaction between tumour cells and the endothelium, which results in 
endothelial production of Ang-2 (Holash et al., 1999).  The consequent vessel 
destabilization and loss of perivascular cell coverage (Fuxe et al., 2011) 
facilitates the extravasation and colonization of cells in distant organs, and their 
subsequent growth into macroscopic metastases (Kienast et al., 2010, Weis et 
al., 2004).  Once lodged in vessels, tumour cells may have a prolonged period of 
intravascular growth during which this vessel destabilization takes place, before 
they finally extravasate (Wong et al., 2002).  Here, we show that VE-PTP 
inhibition attenuates this process, constraining metastatic tumour cells to the 
distant organ’s intravascular compartment and hence slowing metastatic 
progression. 
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Previous studies have shown a reduction in spontaneous metastasis using 
pharmacologic Ang-2 blockade (Koh et al., 2010, Holopainen et al., 2012). In 
these animal models, however, anti-Ang-2 therapy significantly delayed the 
growth of the primary tumours, which remained in situ through the study. This 
delay in primary tumour growth could in itself reduce metastasis (by virtue of a 
reduced primary tumour burden), and the results of these studies cannot confirm 
a specific role for Ang-2 blockade in hindering any step in the metastatic 
cascade. By using a spontaneous metastasis model where therapy was only 
begun after resection of the primary tumour, we confirm a specific influence of 
VE-PTP inhibition upon the metastatic process. Importantly, our experimental 
metastasis data (using 3 different tumour cell lines) provide evidence for 
enhanced vascular integrity as the mechanism behind these observations. 
It is worth noting that as a part of this research, we attempted experiments to 
determine whether AKB-9978 therapy, by enhancing vessel integrity, reduces the 
shedding of cells from established primary tumours into the circulation.  This 
observation has been previously made in transgenic mouse models of tumour 
vessel normalization (Mazzone et al., 2009).  Unfortunately, our attempts to 
replicate these assays using identical methods were unsuccessful due to 
technical failure.  
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8.8 The effects of VE-PTP on the vasculature of established primary 
tumours 
For decades after Folkman first proposed the notion of anti-angiogenic therapy 
for solid tumours (Folkman, 1971), the primary goal of the scientific community 
has been to inhibit the growth of vessels within established tumours, pruning 
them to a point that tumour cells are literally starved of nutrients.  This effort has 
largely manifest through the development of anti-VEGF therapies. 
Unfortunately, it is now clear that traditional anti-angiogenic therapies have not 
achieved this aim.  For example, the anti-VEGF antibody bevacizumab invokes 
almost no meaningful responses in patients with breast, colorectal, or lung 
cancers when given as a monotherapy (reviewed in (Goel et al., 2011)).  
Furthermore, preclinical studies have shown that such therapies can actually 
prune vessels to the extent that tumour hypoxia increases, but tumours do not 
shrink.  This may be in part because reduced tumour perfusion and increased 
tumour hypoxia are known determinants of aggressive behavior, insensitivity to 
chemo- and radiotherapy, and a poor prognosis (Suri et al., 1998, Sorensen et 
al., 2012, Wilson and Hay, 2011, Jain, 2005, Pennacchietti et al., 2003). 
More recently, it appears that the goal posts for vessel-targeted therapies in solid 
tumours have moved.  Pivotal studies using elegant genetic mouse models have 
suggested that more benefits may actually be realized through strategies that 
improve tumour perfusion and oxygenation (Hamzah et al., 2008, Mazzone et al., 
2009).  In these studies, a “normalized” vessel phenotype within tumours was 
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associated with improvements in perfusion, reductions in metastasis, improved 
oxygenation, and an enhanced anti-tumour immune infiltrate.  Importantly, these 
studies did not report a slowing of tumour growth per se, but rather the improved 
efficacy of concomitant therapies (chemotherapy, radiation, immunotherapy), 
which rely on tumour perfusion and oxygenation in order to work (Hamzah et al., 
2008, Mazzone et al., 2009, Jain, 2005).  Finally, clinical data published recently 
also suggests that improvements in perfusion after vessel-targeted therapies 
may actually portend a better prognosis (Batchelor et al., 2013, Emblem et al., 
2013). 
To our knowledge, our data constitutes the first report where a similar vascular 
phenotype has been observed in response to a low molecular weight 
pharmacological agent.  After treating tumour-bearing mice with AKB-9778, we 
observed structural and functional normalization of vessels with a phenotype 
entirely consistent with Tie-2 activation.  
When therapy was commenced at tumour diameter 3mm (once robust 
angiogenesis is underway), we found that AKB-9778 therapy matured tumour 
vessel structure by enhancing pericyte coverage, and increased vessel diameter 
and density (also known effects of Tie-2 signaling).  These changes were in turn 
associated with reduced vessel permeability, improved perfusion, and a 
consequent reduction in hypoxia.  Of note, although the changes in vessel 
diameter that we observed were of the order of 10 percent, one would expect this 
to have a profound impact on perfusion (given Poiseuille’s law stating that 
vascular resistance is inversely proportion to the radius to the fourth power). 
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With specific regard to our findings of enhanced vascular pericyte coverage, it is 
worth noting that our assessment of pericytes was performed using only two of 
an available suite of immunohistochemical markers for pericytes (NG2 and 
desmin).  Pericytes express a number of markers of differentiation such as alpha 
smooth muscle actin (αSMA), desmin, chondroitin sulfate proteoglycan marker 
NG-2 (or high molecular weight melanoma antigen), PDGFRβ (platelet-derived 
growth factor receptorβ), aminopeptidases A and N and RGS5 (regulator of G-
protein signaling).  The regulation of marker expression is still largely not 
understood, and no single marker is able to identify all pericytes (Hall, 2006). For 
example, NG2 expression has been identified as a putative pericyte marker that 
has subsequently been found to be of more limited value, since its expression is 
restricted to arteriolar and capillary perivascular cells (vSMC and pericytes) and 
is absent on venular pericytes (Hall, 2006).  It is thus not surprising that the 
absolute values obtained in experiments assaying pericyte coverage are different 
in experiments using NG2 as opposed to desmin as the pericyte marker.   
Similarly, our data pertaining to effects of AKB-9778 on vascular permeability 
(both in skin and tumour vessels) is more accurately described as demonstrating 
a reduction in vascular leakage.  Both the Miles assay (Fig 43) and measurement 
of BSA extravasation (Fig 35) can be affected not only by a reduction on 
permeability, but also by perfusion pressure and vessel surface area.  Given our 
findings that AKB-9778 increases vessel density and has limited effect on 
systemic blood pressure, the most likely explanation for the reduced 
extravasation of Evan’s Blue and BSA after AKB-9778 therapy is, however, a 
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direct attenuation of permeability – consistent with Tie-2 activation.  Indeed 
although no single finding (enhanced pericyte coverage, increased vessel density 
or diameter, enhanced perfusion, reduced permeability) in our experiments 
serves as complete proof of a more mature, stable vasculature, the constellation 
of findings are collectively highly indicative of this phenotype. 
Our results also support those of a previous study showing that VE-PTP gene 
silencing in embryonic stem cell derived tumours increases vessel diameter (Li et 
al., 2009), and also work suggesting that an increase in vessel diameter after 
loss of VE-PTP function is mediated by Tie-2 activity (Winderlich et al., 2009).  
Importantly, by activating Tie-2 signaling, improving tumour perfusion, and 
ameliorating hypoxia, AKB-9778 therapy also improved radiotherapy efficacy. We 
note that these effects differ from those previously observed after anti-Ang2 
therapies of solid tumours, which characteristically result in narrowed vessels 
with an increase in tumour hypoxia (Koh et al., 2010, Leow et al., 2012). Again, 
this may well relate to the previously discussed differences between anti-Ang2 
therapy and VE-PTP inhibition on the state of Tie-2 activity.  
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8.9 eNOS as a mediator of Tie-2 activity in solid tumours 
In our study, we report that particular changes in tumour vessels seen after VE-
PTP inhibition – namely the increase in vessel diameter and density – are 
specifically related to the activity of the endothelial nitric oxide synthase (eNOS) 
(Goel et al., 2013).   These findings are to some extent not surprising, and are in 
keeping with much of the published literature relating to Tie-2, eNOS, and 
vascular phenotype.  Indeed, previous work has demonstrated that the pro-
angiogenic effects of Tie-2 in a non-tumour setting are, at least in part, eNOS-
dependent (Babaei et al., 2003).   
In the setting of solid tumours, the situation is more complex.   Nitric oxide within 
solid tumours can be synthesized by endothelial cells (by eNOS), but also by 
tumour cells (by inducible NOS, iNOS, and neuronal NOS, nNOS) and stromal 
cells (nNOS) (Fukumura et al., 2006). In each tumour, there exists a “nitric oxide 
gradient” between vessels and surrounding tissue.  In tumours with high levels of 
tumour and/or stromal NO production, the NO gradient is away from the vessel.  
Conversely, in tumours with low levels of tumour and/or stromal NO production, 
the NO gradient is towards the vessel. 
Two reports have previously demonstrated that concentrating intra-tumoural nitric 
oxide around the endothelial compartment normalizes tumour vessel structure 
and function, improving perfusion and reducing hypoxia (Kashiwagi et al., 2005, 
Kashiwagi et al., 2008).  Given that eNOS activation is known to lie downstream 
of Tie-2 in ECs, we speculated that AKB-9778-treated ECs would increase NO 
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production by eNOS, in turn concentrating NO gradients around vessels – 
improving perfusion and reducing hypoxia.   
Importantly, and in contrast to a previous report (Oubaha and Gratton, 2009), we 
not only found an increase in eNOS phosphorylation at the stimulatory ser1177 
residue after VE-PTP inhibition, but also found no increase in phosphorylation at 
the inhibitory Thr495 residue. This finding is in keeping with eNOS biology, where 
counter-regulatory residues are typically phosphorylated and dephosphorylated 
in a manner that yields a unidirectional effect on enzyme activity. By comparing 
the effects of AKB-9778 in wild-type and eNOS-deficient mice, we next 
demonstrated that eNOS activity in the host-organism mediates the vessel 
density and diameter increases seen after AKB-9778 therapy.  
Further studies are required to fully understand involvement of eNOS in AKB-
9778’s effects on blood vessels, tumour progression and dissemination.  Other 
downstream effects of Tie-2 signaling include upregulation of survivin (mitigating 
EC apoptosis) and inhibition of EC cleaved caspase 3 (having the same effect) 
(Huang et al., 2010).  It is conceivable that these mediators, by preventing EC 
death, may also play a significant role in increasing vessel density after VE-PTP 
inhibition. 
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8.10 Limitations of the current study 
Our study has a number of important limitations, which must be acknowledged to 
properly contextualize and interpret the data.   
Firstly, the models used within our experiments have a number of limitations.  As 
discussed earlier, the use of a zebrafish model to study the effects of AKB-9778 
upon embryonic angiogenesis might have little relevance to the mammalian 
situation, as the angiopoietin/Tie system in zebrafish bears many major 
differences to that in humans or mice.  As such, the results of these studies 
should be considered hypothesis generating.   
Furthermore, the mouse models employed also have various limitations.  When 
studying the early phases of tumour growth, we injected tumour cells directly into 
the mammary fat pads of mice.  This model is clearly distinct from the clinical 
reality, in which tumours develop slowly over time, and gradually develop regions 
of hypoxia and new vessel formation.  To this end, we must acknowledge that the 
early stages of neoangiogenesis within our models may not accurately reflect the 
role of VE-PTP in the vessels of spontaneously arising tumours.  
 We also acknowledge that our study contains no information relating to the 
function or presence of VE-PTP in human tumours. Firstly, all of the mouse 
models utilize murine mammary carcinoma cells.  While these have the 
advantage of being implanted into syngeneic mice with competent immune 
systems, there are fundamental differences between human and murine cancers 
  143 
that limit the generalizability of our results. Furthermore, we have yet to perform 
studies examining the presence or role of VE-PTP in human tumour specimens.   
In addition, our studies of the effects of VE-PTP inhibition upon normal tissues 
are somewhat limited.  Our findings of an increase in cutaneous vessel diameter 
and a reduction in permeability may well have significant implications for the 
development of AKB-9778 as a therapeutic, in terms of toxicity.  As such, more 
comprehensive toxicity data is urgently needed – in particular an examination of 
the effects of AKB-9778 on the vasculature of other organs, and on the capacity 
of the cardiovascular system to respond appropriately to changes in systemic 
blood pressure.   
Most importantly, we acknowledge that the understanding of VE-PTP biology, its 
substrates, and interactions is a very young and emerging field.  Our study 
focused almost exclusively on the interaction between VE-PTP and Tie-2, its best 
characterized substrate.  Although the vessel phenotype we observed in our 
mouse tumour models is certainly consistent with a Tie-2 effect, we must 
acknowledge that other key players in the endothelial cell (including VE-Cadherin 
and VEGFR2) may also have direct and indirect interactions with VE-PTP.  We 
have not explored the effects of VE-PTP inhibition on either of these targets in 
any detail, as this was felt to lie beyond the scope of this study.  Nevertheless, it 
is entirely possible that some of our in vivo experimental results are in fact 
related to some of these other complex interactions that VE-PTP has.   
-­‐  
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8.11 Significance of the current findings, and future directions 
VE-PTP was first isolated in 1999, and over the last 15 years, only a small 
number of laboratories worldwide have attempted to characterize its distribution, 
binding partners, and catalytic functions. This work has been almost exclusively 
conducted within in vitro systems, or in mouse models of embryogenesis 
(Fachinger et al., 1999, Baumer et al., 2006, Hayashi et al., 2013, Nottebaum et 
al., 2008, Winderlich et al., 2009). Given the overwhelming evidence that VE-
PTP acts as a negative regulator of Tie-2 activity, its potential has a therapeutic 
target for diseases characterized by vascular immaturity has only recently been 
realized. 
In this regard, we understand that our study presents the first data examining the 
prospective utility of VE-PTP as a therapeutic target (Goel et al., 2013). By 
studying the effects of AKB-9778 within solid tumours, our findings offer two 
major advances.   
First, we show that the in vivo vascular phenotype observed after inhibition of 
VE-PTP’s catalytic domain is one most consistent with Tie-2 activation – that is, 
one characterized by an increased number of mature, functional vessels with 
reduced permeability.  There are now multiple conflicting reports on the potential 
effect of VE-PTP on endothelial barrier integrity (Hayashi et al., 2013, Nottebaum 
et al., 2008, Nawroth et al., 2002), relating to its interaction with different binding 
partners.  While our translational approach does not allow for precise dissection 
of each of these pathways individually, we do demonstrate that the net result of 
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VE-PTP phosphatase inhibition in the tumour setting is one of reduced 
permeability and increased vessel stability.  Indeed as discussed earlier, future 
studies must carefully determine the precise role of VE-PTP’s catalytic and 
extracellular domains, and their relationship to VE-Cadherin, plakoglobin, and 
VEGFR2.      
Second, our results are encouraging for the further development of VE-PTP 
inhibitors as a potential therapy for solid tumours. From a translational 
perspective, our most exciting results are the enhancement of radiation response 
in tumours pre-treated with AKB-9778, and the improvement of mouse survival 
after adjuvant AKB-9778 therapy.  Of course, these results are preliminary, and 
should be replicated by other groups.  We suggest that future studies should 
examine the effects of AKB-9778 in a variety of other solid tumour types (eg. 
colorectal carcinoma, renal cell carcinoma, ovarian carcinoma) where pathologic 
angiogenesis and vascular hyperpermeability are significant clinical problems. 
In addition to its effects on tumour vessels, we suggest that future studies also 
examine the impact of AKB-9778 on the immune cell infiltrate within solid 
tumours.  Tie-2 activation is known to serve an anti-inflammatory function 
(Gamble et al., 2000, Huang et al., 2010), in part mediated by downregulation of 
endothelial adhesion molecules E-selectin, Vascular cell adhesion protein 1 
(VCAM-1), and Intercellular Adhesion Molecule 1 (ICAM-1). It is thus conceivable 
that AKB-9778 could invoke an “anti-inflammatory phenotype” within solid 
tumours, which may or may not prove advantageous depending on precisely 
which immune cell population levels are modified, and in which direction.  In 
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addition, it is possible that AKB-9778, through reduction in tumour hypoxia, could 
have other beneficial effects on the tumour immune microenvironment, such as a 
shift from “pro-tumour” M2 macrophages to “anti-tumour” M1 macrophages 
(Huang et al., 2013, Rolny et al., 2011).   
Other future studies in solid tumours should also determine the expression and 
possible function of VE-PTP in human tumours.  Initially, confirming the presence 
of VE-PTP in the human tumour endothelium is needed to verify its candidacy as 
a therapeutic target.  Furthermore, to gain preliminary insights into a possible 
functional role for VE-PTP in human cancer, it would be valuable to quantify the 
expression level of VE-PTP and phospho-Tie-2 (quantified by 
immunohistochemistry) in a series of breast cancer specimens, and to determine 
if these parameters are correlated with either tumour vessel phenotype or clinical 
outcome.  The latter could easily be determined using one of a large number of 
commercially available tissue microarray resources, which come with patient 
outcome data attached. 
Finally, future preclinical work should begin to explore the effects of combined 
therapy with a VE-PTP inhibitor such as AKB-9778 and more established vessel-
targeted therapies such as VEGF inhibitors.  AKB-9778 has recently been found 
to specifically inhibit the vascular leak induced by excessive VEGF levels (Shen 
et al., 2014).  Furthermore, work from the De Palma laboratory has now revealed 
a specific role for excessive Ang-2 activity (and hence Tie-2 antagonism) in 
resistance to VEGF blockade. (Rigamonti et al., 2014).  In this light, it is 
conceivable that the administration of AKB-9778 together with anti-VEGF therapy 
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could, by opposing the effects of Ang-2, prevent this resistance to VEGF 
blockade.  Furthermore, one could speculate that the more durable vascular 
stabilizing effects of AKB-9778 might mitigate excessive vascular regression 
sometimes seen after anti-VEGF therapy, potentially further enhancing the 
effects of anti-VEGF agents as “normalizers” of the tumour vasculature. 
At the time of writing, AKB-9778 has now entered early phase clinical trials.  
Based on unpublished data from the drug’s manufacturer, together with our 
findings, the compound will be tested in a variety of disease characterized by 
excessive vascular leak, including sepsis and diabetic macular edema.  The 
initial phase 1 study was conducted in patients with macular edema secondary to 
diabetes mellitus, where pathologic angiogenesis and vascular leak are 
responsible for deterioration in vision.  The results of this study showed that AKB-
9778 was well tolerated by patients, and resulted in a meaningful reduction in 
retinal edema in a proportion of patients (Aerpio Therapeutics, 2014).  This 
observation is consistent with our observation that VE-PTP inhibition enhances 
vascular integrity in vivo. If our findings are replicated in other mouse models, 
phase 1 trials of AKB-9778 in cancer patients are anticipated.  Initially, these will 
focus on dose-finding and pharmacokinetic parameters.  
In more general terms, our study is also a timely reminder regarding the potential 
of phosphatase inhibition as a therapeutic tool in cancer.  The human tyrosine 
phosphatome contains a variety of enzymes that dephosphorylate target proteins 
and balance the effects of tyrosine kinases (Julien et al., 2011).  As the growth of 
most tumour cells is driven by kinase activity, drug development has focused 
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almost exclusively on tyrosine kinase inhibitors.  However, certain tyrosine 
phosphatases can also act as oncoproteins, or promote deleterious tumour 
behavior (such as VE-PTP), and inhibiting their catalytic activity could open up a 
wide range of new therapeutic strategies.  
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